愛齊科技 (ALGN) 2018 Q3 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Greetings, and welcome to Align's Q3 2018 Earnings Call. (Operator Instructions) As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Shirley Stacy, VP of Corporate and Investor Communications.

    各位好,歡迎參加 Align 2018 年第三季(Q3)財報電話會議。(接線員指示)提醒各位,本次會議將被錄音。現在我想把會議交給今天的主持人:企業與投資人溝通副總裁 Shirley Stacy。

  • Shirley Stacy - VP of Corporate Communications & IR

    Shirley Stacy - VP of Corporate Communications & IR

  • Good afternoon, and thank you for joining us. I'm Shirley Stacy, Vice President of Corporate Communications and Investor Relations. Joining me for today's call is Joe Hogan, President and CEO; and John Morici, CFO.

    各位下午好,感謝各位加入我們。我是 Shirley Stacy,企業溝通與投資人關係副總裁。今天與我一同參與電話會議的有總裁兼執行長 Joe Hogan,以及財務長 John Morici。

  • We issued third quarter 2018 financial results today via GlobeNewswire, which is available on our website at investor.aligntech.com.

    我們今天透過 GlobeNewswire 發布了 2018 年第三季財務結果,您可在我們的網站 investor.aligntech.com 上查閱。

  • Today's conference call is being audio webcast and will be archived on our website for approximately 12 months. A telephone replay will be available today by approximately 5:30 p.m. Eastern time through 5:30 p.m. Eastern time on November 7. To access the telephone replay, domestic callers should dial (877) 660-6853, with conference number 13683414, followed by #. International callers should dial (201) 612-7415, with the same conference number.

    今天的電話會議將以音訊網路直播,並會在我們的網站上存檔約 12 個月。電話重播將於今日約美東時間下午 5:30 提供,並持續至 11 月 7 日美東時間下午 5:30。(美東時間)要收聽電話重播,美國境內來電者請撥打 (877) 660-6853,會議號碼 13683414,然後按 #。國際來電者請撥打 (201) 612-7415,會議號碼相同。

  • As a reminder, the information that the presenters discuss today will include forward-looking statements, including statements about Align's future events, product outlook and the expected financial results for the fourth quarter of 2018. These forward-looking statements are only predictions and involve risks and uncertainties that are set forth in more detail in our most recent periodic reports filed with the Securities and Exchange Commission.

    提醒各位,今天簡報者所討論的資訊將包含前瞻性陳述,包括關於 Align 未來事件、產品展望,以及 2018 年第四季預期財務結果的陳述。這些前瞻性陳述僅為預測,並涉及風險與不確定性;相關內容在我們最近向美國證券交易委員會(SEC)提交的定期報告中有更詳細的說明。

  • Actual results may vary significantly, and Align expressly assumes no obligation to update any forward-looking statements. We have posted historical financial statements, including the corresponding reconciliations and our third quarter conference call slides on our website, under quarterly results. Please refer to these files for more detailed information. With that, I'll turn the call over to Align Technology's President and CEO, Joe Hogan. Joe?

    實際結果可能會有重大差異,Align 明確表示不承擔更新任何前瞻性陳述的義務。我們已在網站「季度結果」欄位張貼歷史財務報表(包含相對應的調節表)以及第三季電話會議簡報投影片。如需更詳細資訊,請參閱這些檔案。接下來,我把電話交給 Align Technology 總裁兼執行長 Joe Hogan。Joe?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Thanks, Shirley. Good afternoon, and thank you for joining us. On our call today, I'll provide some highlights in the quarter and then briefly discuss the performance of our 2 operating segments, clear aligners and scanners. John will provide more detail on our financial results and discuss our outlook for the fourth quarter. Following that, I'll come back and summarize a few key points and open up the call to questions.

    謝謝你,Shirley。各位下午好,感謝各位加入我們。在今天的電話會議中,我將先提供本季的一些重點,接著簡要說明我們兩個營運部門——透明牙套與掃描器——的表現。John 將更詳細說明我們的財務結果,並討論第四季展望。之後我會回來總結幾個關鍵重點,並開放提問。

  • I'm pleased to report third quarter results with revenue and earnings above our outlook, driven by higher-than-expected Invisalign volume, offset somewhat by lower ASPs and foreign exchange. We also had another record quarter for our iTero scanner business. Q3 Invisalign volume increased 5.5% sequentially and up 35.3% year-over-year, reflecting strength across regions and customer channels as well as strong growth from both teens and adult patients.

    我很高興報告第三季的營收與獲利均高於我們的展望,主要由高於預期的 Invisalign 出貨量所帶動,但部分被較低的平均售價(ASP)與外匯因素所抵銷。我們的 iTero 掃描器業務也再度創下單季新高。第三季 Invisalign 出貨量較前一季成長 5.5%,較去年同期成長 35.3%,反映各地區與客戶通路的強勁表現,以及青少年與成人患者的強勁成長。

  • From a product perspective, we saw strength across Invisalign portfolio, with growth from both comprehensive and noncomprehensive products, reflecting an acceleration in the noncomprehensive category related to expansion of our product portfolio as well this new sales programs and promotions intended to increase adoption and utilization.

    從產品角度來看,我們看到 Invisalign 產品組合全面走強,綜合型與非綜合型產品皆有成長;其中非綜合型類別的加速成長,反映我們擴充產品組合,以及推出新的銷售方案與促銷活動,以提升採用率與使用率。

  • We also saw continued strength from international regions, especially Asia Pacific, which is our second largest region after the Americas in Q3. Finally, during Q3, we trained another record 4,930 doctors, driven by APAC and Latin America, including Invisalign Go doctors, which represent continued expansion of our customer base, especially GP dentists. And Invisalign utilization increased overall to 6.1 cases per doctor, including another record for NA orthodontists.

    我們也看到國際地區持續強勁,尤其是亞太地區;在第三季,亞太是僅次於美洲的第二大地區。最後,在第三季我們再度培訓了創紀錄的 4,930 位醫師,主要由亞太與拉丁美洲帶動,其中包含 Invisalign Go 醫師;這代表我們客戶基礎持續擴張,特別是在一般牙醫(GP)方面。而 Invisalign 整體使用率提升至每位醫師 6.1 例,其中北美矯正醫師也再創新高。

  • Overall, while I'm pleased with the strong volume that we achieved this quarter, there were a couple of unexpected factors that impacted our results.

    整體而言,雖然我對本季達成的強勁出貨量感到滿意,但仍有幾個未預期的因素影響了我們的結果。

  • In Q3, Invisalign ASPs were down sequentially due to a combination of promotional programs, unfavorable foreign exchange and product mix shift, partially offset by price increases across all regions. John will provide more details on this in his commentary.

    第三季 Invisalign 的平均售價(ASP)較前一季下降,原因是促銷方案、不利的外匯變動以及產品組合轉移等因素的綜合影響;但部分被各地區的價格調漲所抵銷。John 將在他的說明中提供更多細節。

  • Now let's turn to the specifics around our quarter, our third quarter results, and let's start with the results of our America regions. For the Americas, Q3 Invisalign case volume was up 5.1% sequentially and 29.1% year-over-year, reflecting better-than-expected volume in both our orthodontist and GP dentist channels, driven by strong teenage case volume from orthodontists and adult patient growth across both customer channels.

    接下來我們來看本季的具體情況與第三季結果,先從美洲地區的表現開始。在美洲,第三季 Invisalign 病例量較前一季成長 5.1%,較去年同期成長 29.1%;這反映我們矯正醫師與一般牙醫(GP)兩個通路的出貨量均優於預期,主要由矯正醫師端的青少年病例量強勁,以及兩個通路的成人患者成長所帶動。

  • For the Americas region, year-over-year growth was led by orthos with another record quarter from North American ortho utilization at 17.4 cases per doctor. Q3 Invisalign utilization for North American GP dentists was up year-over-year at 3.5 cases per doctor, reflecting continued expansion of the GP customer base. We also saw strong volume growth from the Dental Service Organizations, or DSOs, channel, which increased over 40% year-over-year in Q3.

    在美洲地區,年增成長主要由矯正醫師帶動;北美矯正醫師使用率達到每位醫師 17.4 例,再創單季新高。第三季北美一般牙醫(GP)Invisalign 使用率較去年同期提升至每位醫師 3.5 例,反映 GP 客戶基礎持續擴張。我們也看到牙科服務組織(DSO)通路的出貨量強勁成長,第三季較去年同期成長超過 40%。

  • In Q3, we trained over 2,000 new Invisalign doctors in the Americas region, of which 560 were in Latin America alone, primarily Brazil. As the world's second largest market for cosmetic procedures, Brazil is estimated to have more than 1 million new orthodontic case starts each year.

    第三季,我們在美洲地區培訓了超過 2,000 位新的 Invisalign 醫師,其中僅拉丁美洲就有 560 位,主要在巴西。作為全球第二大醫美手術市場,估計巴西每年新增超過 100 萬例矯正病例啟動。

  • In September, we hosted a grand opening event of our new office in São Paulo, Brazil with local doctors to thank them for their ongoing support in helping to build the clear aligner market in Brazil through Invisalign practices.

    9 月,我們在巴西聖保羅(São Paulo)為新辦公室舉辦盛大開幕活動,並邀請當地醫師參與,以感謝他們持續支持,透過 Invisalign 診療協助我們在巴西建立透明牙套市場。

  • We also hosted the grand opening of our newest facility in Costa Rica, located at San Antonio Business Center, with plans to open another multimillion dollar facility located at La Lima later this year. The new facilities will eventually house all of our Costa Rica employees, provide space to accommodate our long-term growth.

    我們也為位於哥斯大黎加、座落於 San Antonio Business Center 的最新設施舉辦盛大開幕,並計畫於今年稍晚在 La Lima 再啟用另一座耗資數百萬美元的設施。這些新設施最終將容納我們所有哥斯大黎加員工,並提供空間以支援我們的長期成長。

  • For international doctors, Q3 was another good quarter with Invisalign case volumes up 6.2% sequentially, reflecting a very strong quarter for APAC, offset by EMEA's seasonality, especially in Southern Europe, markets which typically have extended summer holidays. Year-over-year volume growth of 45.6% for international reflects increased utilization and continued expansion of our customer base.

    就國際醫師而言,第三季同樣表現良好,Invisalign 病例量較前一季成長 6.2%;其中亞太表現非常強勁,但部分被 EMEA 的季節性因素所抵銷,尤其是南歐市場,這些市場通常有較長的暑期假期。國際市場病例量年增 45.6%,反映使用率提升以及客戶基礎持續擴張。

  • In April, Q3 was a strong quarter with Invisalign volume in APAC. Q3 was a strong quarter with Invisalign volumes up 56.4% year-over-year with record shipments for all country markets except Korea. Q3 results reflect record utilization for APAC driven by strong growth from teenage patients as well as growth in the GP dentist channel, up 83.2% compared to last year.

    在 4 月,第三季在亞太地區的 Invisalign 出貨量表現強勁。第三季 Invisalign 出貨量年增 56.4%,除韓國外,各國市場出貨皆創新高。第三季結果反映亞太使用率創新高,主要由青少年患者的強勁成長以及一般牙醫(GP)通路的成長所帶動;GP 通路較去年成長 83.2%。

  • During Q3, we trained 1,730 new doctors in APAC, of which 310 were iGo doctors. We also held several clinical education events across APAC designed to help increase doctors' confidence in and in the adoption of Invisalign treatment, including how critical the iTero scanner is to practice growth.

    第三季期間,我們在亞太培訓了 1,730 位新醫師,其中 310 位為 iGo 醫師。我們也在亞太各地舉辦多場臨床教育活動,旨在提升醫師對 Invisalign 治療的信心與採用度,並強調 iTero 掃描器對診所成長的重要性。

  • In China, we hosted the China Orthodontic Society, or COS, Annual Meeting with over 1,000 doctors. In Japan, we held in Invisalign Forum with clinical speakers focused on teen treatment including Invisalign First cases, adding iTero to their practice and Invisalign G6 innovation. In ANZ, we launched Invisalign First clinical education events and practice marketing activity and received positive feedback with great uptake of Invisalign First cases.

    在中國,我們主辦了中華口腔正畸學會(China Orthodontic Society,簡稱 COS)年會,出席醫師超過 1,000 位。在日本,我們舉辦了 Invisalign 論壇,邀請臨床講者聚焦青少年治療,包括 Invisalign First 病例、在診所導入 iTero,以及 Invisalign G6 創新。在澳洲與紐西蘭(ANZ),我們推出 Invisalign First 臨床教育活動與診所行銷推廣,並獲得正面回饋,Invisalign First 病例採用率表現亮眼。

  • In EMEA, Q3 was down sequentially due to expected seasonality, up to 36.2% year-over-year, reflecting strong growth including the teen segment, which is up over 60% from the prior year. Year-over-year, we saw strength across our core markets, led by France, Iberia and U.K. as well as our key expansion markets led by Central and Eastern Europe.

    在歐洲、中東與非洲(EMEA),第三季因符合預期的季節性因素而較前一季下滑,但年增最高達 36.2%,反映出包含青少年族群在內的強勁成長;其中青少年族群較去年同期成長超過 60%。以年對年來看,我們在核心市場普遍展現強勢表現,由法國、伊比利半島與英國領先;關鍵擴張市場則以中東歐為首。

  • We're also continuing to help expand market for clear aligner treatment with approximately 1,100 newly trained doctors in EMEA, which include 485 iGo-trained GP dentists.

    我們也持續協助擴大透明牙套治療市場,在 EMEA 約有 1,100 位新受訓醫師,其中包含 485 位接受 iGo 訓練的一般牙科醫師(GP)。

  • In Q3, we hosted a number of doctor-centered peer-to-peer events, including our first GP Growth Forum in Copenhagen. We also hosted the grand opening of our new treatment planning facility in Madrid, Spain, which serves the Iberian market. Our Madrid facility aims to increase our commitment to Invisalign-trained doctors in Spain and Portugal and will play a key role in our strategy be closer to our customers and support them in digital treatment planning.

    第三季,我們舉辦多場以醫師為核心的同儕交流活動(peer-to-peer),包括在哥本哈根舉辦的首屆 GP 成長論壇(GP Growth Forum)。我們也在西班牙馬德里為新的治療規劃設施舉行盛大開幕,該設施服務伊比利市場。馬德里設施旨在提升我們對西班牙與葡萄牙 Invisalign 受訓醫師的投入,並將在我們貼近客戶、支援其數位治療規劃的策略中扮演關鍵角色。

  • In October, we hosted our first MEA or Middle East and Africa Forum in Dubai, highlighting the growth of the MEA orthodontic market as well as showcasing our latest advances in digital dentistry that provides practice growth opportunities for dentists.

    10 月,我們在杜拜舉辦首屆 MEA(中東與非洲)論壇,強調 MEA 正畸市場的成長,同時展示我們在數位牙科的最新進展,為牙醫提供診所成長機會。

  • Now turning to the teen segment. In Q3, 98,500 teenagers started treatment with Invisalign clear aligners, an increase of 25.6% sequentially and 41.1% year-over-year, driven by continued strong adoption across all major regions, led by North American orthodontists.

    接著談青少年族群。第三季共有 98,500 名青少年開始使用 Invisalign 透明牙套治療,較前一季成長 25.6%,較去年同期成長 41.1%;成長動能來自各主要地區持續強勁的採用率,其中以北美正畸醫師帶動最為明顯。

  • Q3 was the eighth consecutive quarter that Invisalign teen patient volumes grew faster than adults, reflecting a continued shift towards younger teens and tweens. In Q3, year-over-year Invisalign teen patient growth for North American orthos increased 32.8%, and international doctors were up 60.9%.

    第三季是連續第八個季度,Invisalign 青少年患者量的成長速度快於成人,反映出市場持續轉向更年輕的青少年與學齡前後族群(tweens)。第三季年對年來看,北美正畸醫師的 Invisalign 青少年患者成長 32.8%,國際醫師則成長 60.9%。

  • In Q3, we launched an expanded Invisalign portfolio, including Invisalign First for phase 1 treatment of young patients, age 6 and up. On July 1, we began offering Invisalign First to doctors in North America, EMEA and ANZ and Japan. We shipped almost 2,000 cases to over 600 doctors during Q3.

    第三季,我們推出擴充版 Invisalign 產品組合,其中包括用於年輕患者第一期(phase 1)治療、適用年齡 6 歲以上的 Invisalign First。7 月 1 日起,我們開始向北美、EMEA、ANZ 以及日本的醫師提供 Invisalign First。第三季期間,我們向超過 600 位醫師出貨近 2,000 例。

  • Half of the cases were in North America, and nearly 60% of the Invisalign First patients were 8 to 9 years old. The phase 1 segment of the market is really important for us because it's a large piece of the overall orthodontic cases, but it will also help us gain share in the teenage segment.

    其中一半病例在北美,而 Invisalign First 患者中近 60% 的年齡為 8 至 9 歲。第一期(phase 1)市場區隔對我們非常重要,因為它在整體正畸病例中占比很大,同時也將幫助我們在青少年市場提升市占率。

  • The Invisalign Experience program is a comprehensive way of describing all of Align's activities to engage consumers or potential patients through brand experiences in consumer-friendly settings and environments, including busy mall and lifestyle centers. We started out calling these location stores but realized this is confusing and concerning to some of our doctor customers. We're not selling Invisalign treatment to consumers in these locations. Doctors have always been essential to Invisalign treatment, and a doctor's prescription based on an in-person examination remains the only way that Invisalign treatment can be delivered to a patient even if a consumer learns about the Invisalign brand in new or different ways.

    Invisalign Experience 計畫是一種全面性的方式,用以描述 Align 在消費者友善的場域與環境(包括人潮繁忙的購物中心與生活風格商場)中,透過品牌體驗與消費者或潛在患者互動的各項活動。我們起初將這些稱為「門市據點」(location stores),但後來發現這樣的稱呼會讓部分醫師客戶感到困惑與擔憂。我們並不會在這些地點向消費者銷售 Invisalign 治療。醫師一直是 Invisalign 治療不可或缺的一環;即使消費者以新的或不同方式認識 Invisalign 品牌,仍只有在醫師面對面檢查後所開立的處方下,Invisalign 治療才能提供給患者。

  • In late 2017, we launched Invisalign store pilot program to create and test interactive Invisalign brand experiences at high-traffic retail locations.

    2017 年底,我們推出 Invisalign 門市試點計畫(store pilot program),在高人流零售地點打造並測試互動式的 Invisalign 品牌體驗。

  • Our goal was to educate and engage consumers who might be interested in treatment but aren't showing up as typical consults in offices and get them connected with an Invisalign doctor of their choice. Based on what we have learned in last year and across the first 4 locations in this program, we are expanding this program and will open 8 additional Invisalign Experience locations in the fourth quarter. The first 4 Invisalign Experience locations have shown great progress since opening and have contributed to a significant influx of consumer interest in the orthodontic marketplace surrounding each location.

    我們的目標是教育並吸引可能對治療有興趣、但未以典型方式到診所諮詢的消費者,並讓他們與自己選擇的 Invisalign 醫師建立連結。根據我們在過去一年以及此計畫前 4 個據點所獲得的經驗,我們正在擴大此計畫,並將於第四季再開設 8 個 Invisalign Experience 據點。前 4 個 Invisalign Experience 據點自開幕以來進展良好,並為各據點周邊的正畸市場帶來顯著的消費者關注流入。

  • Key performance metrics suggest that the addition of an Invisalign Experience location can have a significant positive impact or halo effect on overall Invisalign patient growth in the surrounding area. Even among doctors that are not directly participating in the Invisalign Experience program network, it's a new way of creating awareness for brand capturing someone else's attention when they're not even thinking about straightening their teeth. And it benefits all Invisalign practices in the market.

    關鍵績效指標顯示,新增 Invisalign Experience 據點可對周邊地區整體 Invisalign 患者成長帶來顯著的正向影響或「光環效應」(halo effect)。即使是未直接參與 Invisalign Experience 計畫網路的醫師,這也是一種新的品牌認知建立方式,能在消費者甚至尚未想到要矯正牙齒時就吸引其注意。而且這將使市場中所有 Invisalign 診所受益。

  • In Q4, under the Invisalign Experience umbrella, we're launching a major test to the program in New York City with a significant investment in media to reinforce the importance of doctor-led Invisalign treatment and a premium consumer experience to drive qualified consumers to partner doctor practices. On November 5, we will launch a targeted media campaign in New York to take advantage of growing interest in the clear aligner category to capture and direct consumers to Invisalign-branded locations and pilot practices. This test includes an Invisalign-branded kiosk at the Ocular Centre on November 17 as part of the holiday market. Number two, piloting Invisalign Experience branded doctors' practices designed to attract prospective patients, connect them with the Invisalign brand and an Invisalign practice for treatment; and three, empower doctors with new tools, services and support to elevate the patient experience, amplify the message and grow their practice. We're very excited about this program along with several other media campaigns kicking off in Q4 that put doctors at the center of everything we do.

    第四季,在 Invisalign Experience 的架構下,我們將在紐約市對該計畫啟動一項重大測試,並投入大量媒體資源,以強化「由醫師主導的 Invisalign 治療」的重要性,並以高端的消費者體驗將合格的消費者導流至合作醫師診所。11 月 5 日,我們將在紐約推出精準媒體行銷活動,利用透明牙套品類日益升溫的關注度,吸引並引導消費者前往 Invisalign 品牌據點與試點診所。此測試包含:在 11 月 17 日於 Ocular Centre 設置一個 Invisalign 品牌資訊亭(kiosk),作為假日市集的一部分。第二,試行以 Invisalign Experience 品牌打造的醫師診所,旨在吸引潛在患者,讓其與 Invisalign 品牌及 Invisalign 診所建立連結並接受治療;第三,透過新工具、服務與支援賦能醫師,以提升患者體驗、放大訊息並促進診所成長。我們對此計畫感到非常振奮,同時第四季也將啟動數個其他媒體活動,將醫師置於我們所有作為的核心。

  • We've learned a lot from the Invisalign Experience locations and the doctors who have worked with us in the network-to-date. We're applying what we learned and are constantly working to make the Invisalign Experience program better for consumers and better for the practices who opt in to receive those leads.

    我們從 Invisalign Experience 據點以及迄今與我們在網路中合作的醫師身上學到很多。我們正將所學加以應用,並持續努力讓 Invisalign Experience 計畫對消費者更好、也對選擇加入並接收這些名單(leads)的診所更有利。

  • One of the things we've learned from this and other initiatives is that a lot of Invisalign doctors want to do more in their own markets to connect with new consumers. They want to create an Invisalign Experience and practice to connect with potential patients in new ways and want to leverage the total Invisalign iTero digital experience to make starting treatment easier and more convenient for them. We want to help them to do just that.

    我們從此計畫與其他倡議中學到的一點是,許多 Invisalign 醫師希望在其自身市場中做得更多,以連結新的消費者。他們希望打造一種 Invisalign Experience 與診所體驗,以新的方式接觸潛在患者,並希望運用完整的 Invisalign iTero 數位體驗,讓患者開始治療對他們而言更容易、更便利。我們希望協助他們做到這一點。

  • So under the Invisalign Experience program umbrella, we're working with a few doctors in select U.S. markets to explore what an Invisalign Experience looks like in wholly doctor-owned, consumer-focused environment. We're calling this pilot an Invisalign Experience-branded practice and are working with participating doctors to apply some of the lessons and design elements from Invisalign Experience locations to their practices. Some of these pilots will be in markets where we have an Invisalign Experience location, but most will not.

    因此,在 Invisalign Experience 計畫架構下,我們正與美國部分精選市場的少數醫師合作,探索在完全由醫師擁有、以消費者為導向的環境中,Invisalign Experience 會呈現何種樣貌。我們將此試點稱為「Invisalign Experience 品牌診所」(Invisalign Experience-branded practice),並與參與醫師合作,把 Invisalign Experience 據點的一些經驗與設計元素導入其診所。其中部分試點將位於我們已有 Invisalign Experience 據點的市場,但大多數不會。

  • Doctor-owned Invisalign Experience practices don't compete with the line. We're all working together to reach consumers in new ways. We'll share more progress with you in details on the different ways we're partnering with doctors under the Invisalign Experience umbrella in the coming quarter.

    由醫師擁有的 Invisalign Experience 診所不會與公司競爭。我們正共同合作,以新的方式觸及消費者。在接下來的一季,我們將就我們在 Invisalign Experience 架構下與醫師合作的不同方式,向各位分享更詳細的進展。

  • Our Smile Concierge program that we launched at the beginning of 2017 is continuing to help more consumers start Invisalign treatment by shortening their research cycle and connecting them with an active Invisalign doctor. Year-to-date, we scheduled over 74,000 Invisalign consultations in the U.S., which equates to connecting hundreds of consumers to Invisalign doctors every day, providing leads they might not otherwise have had. The Smile Concierge service has also expanded outside the United States with teams in Singapore, Brazil, Australia and the U.K.

    我們於 2017 年初推出的 Smile Concierge 計畫,持續透過縮短消費者的研究決策週期並將其連結至活躍的 Invisalign 醫師,協助更多消費者開始 Invisalign 療程。截至目前為止,我們在美國已安排超過 74,000 次 Invisalign 諮詢,這相當於每天將數百位消費者連結至 Invisalign 醫師,提供他們原本可能無法取得的潛在客戶名單。Smile Concierge 服務也已擴展至美國以外地區,在新加坡、巴西、澳洲與英國均設有團隊。

  • And Q3 was a very strong quarter across the board for iTero scanners and services business with better-than-expected revenues, which were up 37.2% sequentially and 79.1% year-over-year. Record Q3 results reflect commercialization of the iTero Element 2 and Element Flex scanners, especially for restorative GP dentists in North America. Continue to rollout with DSO partners and increased sales internationally, including China, we have also begun to manufacture the iTero Element.

    此外,第三季 iTero 掃描儀與服務業務整體表現非常強勁,營收優於預期,較前一季成長 37.2%,較去年同期成長 79.1%。第三季創紀錄的成果反映了 iTero Element 2 與 Element Flex 掃描儀的商業化推進,特別是在北美的修復領域一般牙醫(GP)市場。隨著與 DSO 夥伴持續推進導入並提升國際銷售(包括中國),我們也已開始製造 iTero Element。

  • Using the iTero scanners for Invisalign case admission in place of PVS impressions continues to grow and remains a positive catalyst for Invisalign utilization. For Q3, total Invisalign cases submitted with a digital scanner in the Americas was essentially flat at 68.8%. International scans increased 51.6% of total Invisalign cases submitted in Q3. We are very excited about the continued progress we have made with the iTero business and remain confident that it will continue to help drive our overall growth and help increase adoption of Invisalign treatment.

    以 iTero 掃描儀取代 PVS 印模來提交 Invisalign 病例的使用持續成長,並仍是推動 Invisalign 使用率的正向催化因素。第三季,美洲地區以數位掃描儀提交的 Invisalign 病例占比基本持平,為 68.8%。國際市場掃描提交占第三季 Invisalign 病例總數的比例提升至 51.6%。我們對 iTero 業務持續取得的進展感到非常振奮,並仍有信心它將持續推動我們的整體成長,並協助提升 Invisalign 療程的採用率。

  • Before I turn the call over to John, I want to share with you some important news with you today regarding our Chief Marketing Officer, or CMO, Raph Pascaud. After more than 8 years in the line, Raph has made a personal decision to reduce his responsibilities and transition to a part-time position in order to spend more time with his family. As a result, we have began an executive search for a Chief Marketing Officer and we'll be working to find a replacement for Raph's marketing position over the coming months. Once we've hired a new CMO, Raph will transition his marketing responsibilities to that leader, but he will continue to lead the business development and strategy for the company. Raph will also remain on the executive management committee, reporting directly to me.

    在我把電話交給 John 之前,我想與各位分享今天一則關於我們行銷長(Chief Marketing Officer,CMO)Raph Pascaud 的重要消息。在公司服務超過 8 年後,Raph 基於個人考量決定降低職責並轉任兼職,以便有更多時間陪伴家人。因此,我們已開始為行銷長一職進行高階主管招募,並將在未來數月內尋找接替 Raph 行銷職務的人選。一旦我們聘任新的 CMO,Raph 將把行銷職責移交給該位領導者,但他仍將持續負責公司的業務發展與策略。Raph 也將繼續留在高階管理委員會,並直接向我匯報。

  • Raph's contributions to Align have been significant. He's held numerous leadership positions across the organization, including Head of International, Marketing, Product Portfolio and Business Development, as well as overseeing the iTero business. We're fortunate that Raph will remain directly engaged in our strategy and overall business plans and will be able to help the new CMO come up to speed quickly. Until then, nothing changes and Raph remains Align's CMO and SVP, Product Portfolio and Business Development. We're sharing this news with you today so we can openly recruit for a new CMO and so Raph can begin to develop a transition plan with his global marketing team.

    Raph 對 Align 的貢獻相當重大。他在組織內擔任過多項領導職務,包括國際業務負責人、行銷、產品組合與業務發展,並曾監督 iTero 業務。我們很幸運 Raph 將持續直接參與我們的策略與整體業務計畫,並能協助新任 CMO 迅速上手。在此之前,一切維持不變,Raph 仍是 Align 的 CMO 以及產品組合與業務發展資深副總裁(SVP)。我們今天與各位分享此消息,是為了能公開招募新的 CMO,並讓 Raph 能開始與其全球行銷團隊制定交接計畫。

  • With that, I'll now turn the call over to John.

    接下來,我把電話交給 John。

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Thanks, Joe. Now for our Q3 financial results. Total revenue for the third quarter was $505.3 million, up 3.1% from the prior quarter and up 31.2% from the corresponding quarter a year ago. Year-over-year revenue growth was favorable in all regions. Clear aligner revenue of $421.1 million was down 1.4% sequentially, driven by lower ASPs as a result of higher-than-expected discounts and unfavorable foreign exchange, partially offset by increased volume.

    謝謝你,Joe。接著說明我們第三季的財務結果。第三季總營收為 5.053 億美元,較前一季成長 3.1%,較去年同期成長 31.2%。各地區的年增營收成長皆表現良好。透明牙套營收為 4.211 億美元,較前一季下滑 1.4%,主要受平均售價(ASP)下降影響,原因是折扣高於預期以及不利的外匯因素;部分由出貨量增加所抵銷。

  • Year-over-year, clear aligner revenue growth of 25% reflected strong Invisalign shipment growth across all customer channels and geographies and was partially offset by lower ASPs. As Joe mentioned earlier in his remarks, Q3 Invisalign ASPs were down sequentially and year-over-year due to a combination of promotional programs, unfavorable foreign exchange and product mix, partially offset by price increases across all regions.

    以年增來看,透明牙套營收成長 25%,反映 Invisalign 出貨量在所有客戶通路與各地理區域皆強勁成長,但部分被較低的 ASP 所抵銷。如 Joe 先前所提,第三季 Invisalign 的 ASP 較前一季及去年同期下降,原因綜合了促銷方案、不利外匯與產品組合影響;但各地區的價格調升部分抵銷了上述影響。

  • In Q3, we offered new product promotions designed to increase adoption of Invisalign treatment, and we saw much higher-than-expected uptake on some of these promotions. In addition, the beginning of the year, we created a more robust North America Advantage customer loyalty program, which has been very favorably received by our doctors. The new Advantage Program changed to a semiannual discount qualification period instead of a quarterly one, with additional tiers that provide doctors with more incentive to move up the tiers by increasing their Invisalign case volume. As a result, more doctors are moving up in tiers and achieving higher overall discounts than they were under the prior program.

    第三季我們推出新的產品促銷,旨在提升 Invisalign 療程的採用率,而其中部分促銷的參與度遠高於預期。此外,在年初我們打造了更完善的北美 Advantage 客戶忠誠計畫,並獲得醫師非常正面的回饋。新的 Advantage 計畫將折扣資格認定期間由每季改為每半年一次,並新增更多等級,透過提高 Invisalign 病例量,為醫師提供更大的誘因以晉升等級。因此,更多醫師正在提升等級,並取得較先前方案更高的整體折扣。

  • In Q3, we also saw a shift towards lower ASP non-comprehensive products. Some of which is tied to promotions and some is tied to continued progress, expanding our business with a GP dentist and DSOs. Specifically, Q3 ASPs were down by approximately $85 and increased $24 of unfavorable foreign exchange and down $80 year-over-year and includes $15 of unfavorable foreign exchange. Total Q3 Invisalign shipments of 319,300 cases were up 5.5% sequentially and up 35.3% year-over-year, driven by growth in the Americas and APAC, partially offset by seasonality in EMEA.

    第三季我們也看到產品組合轉向 ASP 較低的非全方案(non-comprehensive)產品。其中一部分與促銷有關,另一部分則與我們持續推進業務、擴大在一般牙醫(GP)與 DSO 的布局有關。具體而言,第三季 ASP 約下降 85 美元,其中包含 24 美元來自不利外匯影響;較去年同期則下降 80 美元,其中包含 15 美元來自不利外匯影響。第三季 Invisalign 總出貨量為 319,300 例,較前一季成長 5.5%,較去年同期成長 35.3%,主要由美洲與亞太(APAC)成長帶動,部分被歐洲、中東與非洲(EMEA)的季節性因素所抵銷。

  • For Americas orthodontists, Q3 Invisalign case volume was up 8.6% sequentially and up 32.2% year-over-year. For Americas GP dentists, Invisalign case volume was down 0.3% sequentially and up 24.2% year-over-year. For international doctors, Invisalign case volume was up 6.2% sequentially and up 45.6% year-over-year. Our scanner and services revenue for the third quarter was $78.2 million, up 37.2% sequentially due to volume increases in North America DSO contracts and higher volume in APAC. Year-over-year revenue was up 79.1%, primarily due to higher scanner units across regions.

    就美洲矯正醫師而言,第三季 Invisalign 病例量較前一季成長 8.6%,較去年同期成長 32.2%。就美洲一般牙醫(GP)而言,Invisalign 病例量較前一季下滑 0.3%,較去年同期成長 24.2%。就國際醫師而言,Invisalign 病例量較前一季成長 6.2%,較去年同期成長 45.6%。第三季我們的掃描儀與服務營收為 7,820 萬美元,較前一季成長 37.2%,主要因北美 DSO 合約帶動的出貨量增加,以及亞太地區更高的出貨量。年增營收成長 79.1%,主要由各地區掃描儀出貨台數增加所致。

  • Moving on to gross margin. Third quarter overall gross margin was 73.6%, down 1 point sequentially and down 2.3 points year-over-year. Clear aligner gross margin for the third quarter was 75.3%, down 1.2 points sequentially, primarily due to lower ASP described earlier. Clear aligner gross margin was down 2.6 points year-over-year, primarily due to lower ASP and regional expansion of our manufacturing activities.

    接著談毛利率。第三季整體毛利率為 73.6%,較前一季下降 1 個百分點,較去年同期下降 2.3 個百分點。第三季透明牙套毛利率為 75.3%,較前一季下降 1.2 個百分點,主要因前述 ASP 較低所致。透明牙套毛利率較去年同期下降 2.6 個百分點,主要因 ASP 較低以及我們製造活動的區域擴張所致。

  • Scanner gross margin for the third quarter was 63.9%, up 4.4 points sequentially and up 3.9 points year-over-year, primarily due to higher manufacturing efficiencies.

    第三季掃描器毛利率為63.9%,較前一季上升4.4個百分點,較去年同期上升3.9個百分點,主要由於製造效率提升。

  • Q3 operating expenses were $246.6 million, up sequentially 1.5% and up 27.3% year-over-year. The increase in operating expenses reflects continued investment in our R&D and go-to-market activities.

    第三季營業費用為2.466億美元,較前一季增加1.5%,較去年同期增加27.3%。營業費用的增加反映我們持續投資於研發以及市場推廣(go-to-market)活動。

  • Our third quarter operating income was $125.2 million, up 2.1% sequentially and up 26.8% year-over-year. The sequential increase in operating income is primarily due to higher revenues. On a year-over-year basis, the increase in operating income, primarily reflects leverage from operating expenses on higher revenues from both clear aligner, and scanner and services.

    第三季營業利益為1.252億美元,較前一季增加2.1%,較去年同期增加26.8%。營業利益的季增主要來自營收提高。以年增來看,營業利益的增加主要反映在更高營收下營業費用的槓桿效益,營收來源包括隱形矯正器,以及掃描器與服務。

  • Our third quarter operating margin was 24.8%, down 0.2 points sequentially and down 0.8 points year-over-year. The sequential decrease in operating margin is primarily due to lower gross margin from lower ASPs as mentioned above, offset by increased operating expense leverage.

    第三季營業利益率為24.8%,較前一季下降0.2個百分點,較去年同期下降0.8個百分點。營業利益率的季減主要由於如前所述,ASP下降導致毛利率降低,但部分被營業費用槓桿效益提升所抵銷。

  • On a year-over-year basis, the decrease in operating margin is primarily due to lower gross margin from ASPs and continued expansion of our regional manufacturing facilities, offset by higher operating expense leverage.

    以年增來看,營業利益率下降主要由於ASP導致的毛利率降低,以及我們持續擴張區域製造設施所致,但部分被更高的營業費用槓桿效益所抵銷。

  • With regards to the third quarter tax provision. Our tax rate was 19.4%, which includes a $24.7 million release of unrecognized tax benefits due to a statute lapse, partially offset by a $20.2 million charge related to nondeductible officers' compensation based on recent IRS guidance. Third quarter diluted earnings per share was $1.24, down $0.06 sequentially and up $0.23 compared to the prior year.

    關於第三季所得稅費用。我們的稅率為19.4%,其中包括因法定期限屆滿而回轉2,470萬美元未確認稅務利益,部分被一筆2,020萬美元費用所抵銷,該費用與依據近期美國國稅局(IRS)指引、不可扣抵的高階主管薪酬相關。第三季稀釋每股盈餘為1.24美元,較前一季下降0.06美元,較去年同期增加0.23美元。

  • Moving on to the balance sheet. As of the third quarter, cash, cash equivalents and marketable securities, including both short and long-term investments were $613.2 million. This compared to $720.7 million at the end of Q2, a decrease of approximately $107.5 million, primarily due to our stock repurchases during the quarter. Of our $613.2 million of cash, cash equivalents and marketable securities, $228 million was held in the U.S. and $385.2 million was held by our international entities.

    接著看資產負債表。截至第三季末,現金、約當現金與有價證券(包含短期與長期投資)為6.132億美元。相較於第二季末的7.207億美元,減少約1.075億美元,主要由於本季進行庫藏股回購。在6.132億美元的現金、約當現金與有價證券中,2.28億美元持有於美國,3.852億美元由海外子公司持有。

  • Q3 accounts receivable balance was $420.3 million, up approximately 12.3% sequentially. Our overall days sales outstanding, or DSOs, was 75 days, up 7 days sequentially and flat as of Q3 last year.

    第三季應收帳款餘額為4.203億美元,較前一季增加約12.3%。整體應收帳款週轉天數(DSO)為75天,較前一季增加7天,與去年第三季持平。

  • Cash flow from operations for the third quarter was $96.3 million, down $21.8 million compared to the prior year, primarily due to the timing of pending tax refunds. Free cash flow for the third quarter, defined as cash flow from operations less capital expenditures, amounted to $42.6 million.

    第三季營運活動現金流為9,630萬美元,較去年同期減少2,180萬美元,主要由於待處理退稅款的時點影響。第三季自由現金流(定義為營運活動現金流減資本支出)為4,260萬美元。

  • Capital expenditures for the third quarter were $53.7 million, primarily related to our continued investment in increasing aligner capacity and facilities.

    第三季資本支出為5,370萬美元,主要與我們持續投資以提升隱形矯正器產能與設施相關。

  • During Q3 of 2018, we repurchased 150 million of our stock against our stock buyback authorizations and have $550 million still available for repurchase under the May 2018 repurchase program.

    在2018年第三季,我們依據股票回購授權回購了1.5億美元的公司股票;在2018年5月回購計畫下,仍有5.5億美元可供回購。

  • With that, let's turn to our Q4 outlook and the factors that inform our view, starting with the demand outlook. We expect Q4 international volume to increase sequentially from Q3, reflecting the EMEA market seasonality, stronger period following summer holidays in Q3, offset somewhat by seasonality -- seasonal slower Q4 period in APAC as China comes off a very strong summer period.

    接下來我們看第四季展望,以及支撐我們觀點的因素,先從需求展望開始。我們預期第四季國際市場的量將較第三季呈季增,反映EMEA市場的季節性(第三季暑假後的較強期間),但部分會被APAC第四季季節性較慢所抵銷,因中國在夏季期間表現非常強勁後進入回落。

  • For Americas, better-than-expected Q3 volume was driven in part due to some promotions that have been discontinued. We expect Q4 Americas volume to increase slightly sequentially. We expect our iTero business to be flat sequentially in Q4, coming off a very strong Q3, as we continue to invest in growing the iTero business across all regions including China, and an ongoing rollout with DSO partners in the U.S. We continue to expect SmileDirectClub volume to be at a minimal contractual level and we -- and are anticipating the decrease sequentially from Q3.

    就美洲而言,第三季量優於預期,部分是由於一些促銷活動帶動,但這些促銷已經停止。我們預期第四季美洲量將較第三季小幅季增。我們預期第四季iTero業務將與第三季持平(第三季非常強勁),同時我們持續投資在所有地區(包括中國)擴大iTero業務,並在美國與DSO合作夥伴持續推進導入。我們仍預期SmileDirectClub的量將維持在最低合約水準,且我們——並預期其量將較第三季呈季減。

  • With this as a backdrop, we expect the fourth quarter to shape up as follows: Invisalign case volume is expected to be in the range of 330,000 to 335,000 cases, up approximately 29.4% to 31.4% year-over-year. We expect Q4 revenues to be in the range of $505 million to $515 million, an increase of approximately 20% to 22% year-over-year, reflecting strong growth for Invisalign volumes, offset by lower ASPs, due primarily to ongoing promotional discounts, the effect of our new Advantage customer loyalty program, continued mixed shift towards noncomprehensive products as well as foreign exchange.

    在此背景下,我們預期第四季表現如下:Invisalign病例量預計介於33萬至33.5萬例,較去年同期增加約29.4%至31.4%。我們預期第四季營收介於5.05億至5.15億美元,較去年同期增加約20%至22%,反映Invisalign量的強勁成長,但部分被較低的ASP所抵銷;ASP下降主要由持續的促銷折扣、新的Advantage客戶忠誠計畫的影響、產品組合持續轉向非全方案產品,以及外匯因素所致。

  • We expect Q4 gross margin to be in the range of 72.3% to 73%, reflecting lower margins as we begin to produce clear aligners in our new manufacturing facility in Ziyang, China, where we will initially have higher fixed costs spread across very low volumes. We expect Q4 operating expenses to be in the range of $248 million to $253 million. Q4 operating margin should be in the range of 23.2% to 23.9%. Our effective tax rate should be approximately 22.5%. We expect approximately $2 million equity loss related to our share of SmileDirectClub, and diluted shares outstanding should be approximately 81.3 million, exclusive of any share repurchases.

    我們預期第四季毛利率介於72.3%至73.0%,反映當我們開始在中國資陽的新製造廠生產隱形矯正器時,毛利率將較低;初期固定成本較高且分攤在非常低的產量上。我們預期第四季營業費用介於2.48億至2.53億美元。第四季營業利益率應介於23.2%至23.9%。我們的有效稅率應約為22.5%。我們預期與SmileDirectClub相關、按持股比例認列的權益法損失約200萬美元;稀釋流通在外股數約為8,130萬股,不包含任何股票回購的影響。

  • Taken together, we expect our Q4 diluted earnings per share to be in the range of $1.10 to $1.15. In addition, as we continue our operational expansion efforts, we expect CapEx for Q4 to be approximately $50 million to $55 million. And we expect depreciation and amortization to be $15 million to $16 million.

    綜合以上,我們預期第四季稀釋每股盈餘介於1.10至1.15美元。此外,隨著我們持續推動營運擴張,我們預期第四季資本支出約為5,000萬至5,500萬美元。我們預期折舊與攤銷為1,500萬至1,600萬美元。

  • Now let me turn to our view for the full year 2018. Based on our Q4 guidance, we expect -- we continue to expect 2018 total revenue growth rate to be above our long-term model and in the low 30s. We expect Invisalign revenue and volume growth to also be in the low 30s. Taken together, we continue to expect operating margin for the full year 2018 to be slightly up from 2017 operating margin of 24%.

    接著談我們對2018年全年的看法。根據第四季指引,我們預期——我們仍預期2018年全年總營收成長率將高於我們的長期模型,約在30%出頭。我們預期Invisalign營收與量的成長也將在30%出頭。綜合而言,我們仍預期2018年全年營業利益率將較2017年的24%略為上升。

  • With that, I'll turn it back over to Joe for final comments. Joe?

    接下來我把時間交回給Joe做最後評論。Joe?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Thanks, John. Overall, Q3 was another good quarter with strong growth for both the Invisalign and iTero businesses. Our performance reflects continued success in driving adoption and utilization across all region and customer channels as well as an increased traction in new expansion markets with our DSO partners. We have a huge market opportunity ahead to connect millions of consumers with Invisalign doctors for orthodontic treatment. And whether it's through traditional routes in the doctor's office or through new consumer-friendly approaches like the Invisalign Experience program, we are committed to a doctor in the center of everything we do.

    謝謝,John。整體而言,第三季又是一個表現良好的季度,Invisalign與iTero兩項業務皆有強勁成長。我們的表現反映我們持續成功推動各地區與各客戶通路的採用與使用率提升,並且透過DSO合作夥伴在新拓展市場取得更高的進展。我們面前有龐大的市場機會,可將數以百萬計的消費者與提供Invisalign療程的醫師連結起來,以進行齒顎矯正治療。無論是透過醫師診所內的傳統方式,或透過如Invisalign Experience計畫等更貼近消費者的新方式,我們都致力於以醫師為核心,貫穿我們所做的一切。

  • Align is the best positioned company to help doctors successfully navigate their rapidly changing dental market. And we're excited to be guiding them through this digital transformation.

    Align 是最具優勢、最能協助醫師成功因應快速變化牙科市場的公司。我們也很期待能引導他們完成這場數位轉型。

  • I look forward to following up with many of you in the coming weeks at various conferences and industry meetings, including the Invisalign Ortho Summit in Las Vegas next month, where approximately 2,500 doctors and their staff will spend 2 days sharing Invisalign and iTero best practices in one of our most important peer-to-peer clinical education events.

    我期待在接下來幾週於各項研討會與產業會議上與各位中的許多人再度交流,其中包括下個月在拉斯維加斯舉辦的 Invisalign Ortho Summit,屆時約 2,500 位醫師及其團隊將用 2 天時間,在我們最重要的同儕對同儕臨床教育活動之一中,分享 Invisalign 與 iTero 的最佳實務。

  • With that, I'll turn the call over to the operator. Operator?

    接下來,我把電話會議交給接線員。接線員?

  • Operator

    Operator

  • (Operator Instructions) Our first question comes from the line of Robert Jones from Goldman Sachs.

    (接線員指示) 我們的第一個問題來自高盛(Goldman Sachs)的 Robert Jones。

  • Robert Patrick Jones - VP

    Robert Patrick Jones - VP

  • I guess, just to start on the lower ASPs, which you guys provided some details around, at least the areas that impacted it. And John, if I heard you correctly, it sounds like of the $85 sequential decline, if I remove FX, it would have been more like $60, $61 sequential decline. So of that decline, I was hoping maybe you could just break down how much of that came from promotions versus mix shift? And then I guess the follow-up would be, I don't necessarily remember you guys talking so much about the additional promotional programs, so curious if there was something in the marketplace that kind of force you to react to put the promotions in place or if this was something that was always planned and maybe the uptake was just greater than you thought?

    我想先從較低的 ASP 談起,你們已提供了一些細節,至少說明了影響它的面向。John,如果我沒聽錯,聽起來在連續下滑的 85 美元之中,若扣除匯率(FX)因素,連續下滑幅度會更像是 60、61 美元。因此,針對這段下滑,我希望你能拆解一下,其中有多少來自促銷、又有多少來自產品組合轉移(mix shift)?接著我想追問的是,我不太記得你們過去談過這麼多額外的促銷方案,所以也好奇是否市場上發生了某些事情迫使你們採取反應、推出促銷,或這其實原本就有規劃,只是採用率比你們預期更高?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Yes. Bob. This is John. On the remaining piece that's left, about half of the drop in ASPs was due to mix, it was mix shift to the lower stage products, and about the other half or $30 or so was related to those promotions.

    是的。Bob。我是 John。在剩下那一部分中,ASP 下滑約有一半是由組合因素造成,也就是產品組合轉向較低階段(lower stage)產品;另外一半、約 30 美元左右,則與那些促銷有關。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • And yes, Bob, it's Joe. Look, obviously on the Advantage Program and the special programs we ran for the quarter, we do this all the time. We're trying to encourage customer stickiness. We're checking out different segments of the marketplace. We do this all the time. But in this case, what happened is we incentivized the upper end of our customer segment. We did not get engagement in the lower end that we anticipated. And so in that sense, we will shut that thing down. We won't repeat it again. We obviously learned from it, and we move on.

    是的,Bob,我是 Joe。你看,關於 Advantage Program 以及我們本季執行的特別方案,我們一直都會做這類事情。我們希望提升客戶黏著度。我們也在檢視市場中不同的區隔。這些我們一直都在做。但這次發生的情況是,我們激勵的是客戶族群中較高端的那一段。而在較低端的部分,我們沒有得到原先預期的參與度。因此從這個角度來看,我們會把這項方案停掉。我們不會再重複做。我們顯然從中學到經驗,然後繼續往前。

  • Robert Patrick Jones - VP

    Robert Patrick Jones - VP

  • And then I guess, Joe, just a follow-up on that then. As we think about ASPs for 4Q and then more importantly, beyond 4Q, is it safe to assume that FX will be what it is but that the -- at least a portion of the headwind from the promotion should normalize?

    那我想追問一下,Joe。當我們思考第 4 季的 ASP,以及更重要的是第 4 季之後的 ASP 時,是否可以假設匯率(FX)就維持其現狀,但至少促銷帶來的部分逆風會回歸正常?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes, that's correct. Think about it as flat, Bob.

    是的,沒錯。把它視為持平即可,Bob。

  • Operator

    Operator

  • Our next question comes on the line of Brandon Couillard from Jefferies.

    我們的下一個問題來自 Jefferies 的 Brandon Couillard。

  • Brandon Couillard - Equity Analyst

    Brandon Couillard - Equity Analyst

  • Maybe, John, in terms of the aligner gross margins in the quarter, can you break out the impact of the manufacturing capacity expansions relative to ASPs? And as you look into 2019, given we're kind of balancing along the low end of your 3 to 5-year model here at about 73%, would it be logical to expect year-over-year expansion in terms of the aligner margins as you start to soak up some of that new manufacturing capacity expansions?

    John,關於本季隱形矯正器(aligner)的毛利率,你能否拆解一下製造產能擴張相對於 ASP 的影響?另外展望 2019 年,鑑於我們目前大致落在你們 3 到 5 年模型低端、約 73% 左右,是否可以合理預期隱形矯正器毛利率會出現年對年擴張,因為你們開始逐步吸收(soak up)這些新增的製造產能?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Yes. You're right, Brandon. I mean, what we see -- initially because of the low volumes, we'll see more of that fixed cost over that low volume. So that's 0.5 to 1 point impact due to the manufacturing start-up. And then as we get more efficient, we should see some improvement as we go forward related to those manufacturing costs.

    是的。你說得對,Brandon。我的意思是,我們看到的是——一開始因為產量較低,固定成本會分攤在較低的產量上。因此製造端啟動(start-up)會帶來 0.5 到 1 個百分點的影響。接著隨著效率提升,往後我們應該會看到與這些製造成本相關的一些改善。

  • Brandon Couillard - Equity Analyst

    Brandon Couillard - Equity Analyst

  • And then one for Joe. The OpEx guidance for the fourth quarter implies the slowest year-over-year growth rate in a few years now. To what extent are you beginning to see perhaps some diminishing returns from incremental investments be they feet on the street or marketing or otherwise perhaps in some of the more international and emerging markets?

    接著一題給 Joe。你們對第 4 季的營業費用(OpEx)指引,意味著這幾年來最慢的年對年成長率。你們在多大程度上開始看到增量投資的邊際效益遞減——不論是前線人員(feet on the street)、行銷或其他投入——特別是在一些更國際化與新興市場?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Brandon, I think if you look at our growth, I mean, our growth is above 30% right now. So we don't see any diminishing returns in that sense. Remember, we had a really -- we had a big third quarter when you look at our volume growth versus other years. So the normal sequential kind of iteration that we go through between third and fourth, we don't really believe it's going to be as dramatic as it has been in the past. And so this doesn't reflect anything from a market standpoint. Remember, as you look at our performance overall, international markets performed extremely very well, okay? We still had incredible shipments in North America from an Invisalign standpoint. We also had great iTero too. So primarily, what we're looking at is what we have with these promotions in the sense that the ASPs driven by them and the corrections we have to make sure as we go into the fourth quarter.

    Brandon,我想如果你看我們的成長,我們目前的成長率在 30% 以上。所以從這個角度來看,我們沒有看到任何邊際效益遞減。記得,當你比較我們的量成長與其他年度時,我們第 3 季表現非常——我們第 3 季很強。因此,我們在第 3 季到第 4 季之間通常會經歷的那種正常的連續變化(sequential iteration),我們不認為會像過去那樣劇烈。所以這並不反映任何市場面的問題。記得,從整體表現來看,國際市場表現非常、非常好,好嗎?從 Invisalign 的角度來看,我們在北美的出貨仍然非常亮眼。iTero 也同樣表現很棒。因此,我們主要關注的是這些促銷所帶來的影響——也就是它們所驅動的 ASP,以及我們必須做出的修正,以確保在進入第 4 季時到位。

  • Operator

    Operator

  • Our next question comes from the line of Jon Block from Stifel.

    我們的下一個問題來自 Stifel 的 Jon Block。

  • Jonathan David Block - MD & Senior Equity Research Analyst

    Jonathan David Block - MD & Senior Equity Research Analyst

  • First one, John, I think you mentioned flat scanner revs Q-over-Q, and I'm going to make some other assumptions, but I'm backing into around a $1,200 Invisalign ASP for 4Q '18 based on your volume guidance. 3Q '18, I believe, was 1,230 on a worldwide basis. You mentioned some of the promotions that will run in 3Q will not be repeated. So why the continued decline on the worldwide ASP into 4Q, and then do we think about extrapolating that 1,200, if I'm right, out to '19 for -- and then I've got a follow-up.

    第一題,John,我想你提到掃描儀營收(scanner revs)季對季持平;我再做一些其他假設後,依據你們的量指引,我推算 2018 年第 4 季 Invisalign 的 ASP 約為 1,200 美元。我相信 2018 年第 3 季全球口徑約為 1,230。你提到第 3 季的一些促銷在第 4 季不會重複。那為什麼全球 ASP 在第 4 季仍會持續下滑?另外,如果我推算的 1,200 沒錯,我們是否應該把這個數字外推到 2019 年來看——我還有一個追問。

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Yes, Jon. I would look at Q4 as continued mix [effects] that we have. So as we are the low stage that we see, that we've seen through Q3, some of the mix shift that's happening, that will continue into Q4. But like we had said, those promotions that we had, those specific promotions that were driving down some of the ASPs in Q3 will not continue into Q4.

    是的,Jon。我會把第 4 季視為我們持續受到組合(mix)[影響]。因此,隨著我們看到的較低階段(low stage)——也就是我們在第 3 季一路看到的——部分正在發生的組合轉移,會延續到第 4 季。但如同我們所說,第 3 季那些拉低部分 ASP 的特定促銷,在第 4 季不會延續。

  • Jonathan David Block - MD & Senior Equity Research Analyst

    Jonathan David Block - MD & Senior Equity Research Analyst

  • Okay. And then Joe, you may have answered this to Robert's question earlier. So I apologize if this is redundant. But I think it's important, obviously, with the focus on the promotion. So can you be a little bit more clear that the promotions that you ran in the quarter, you hear the word promotions at the same time that 2 or 3 comprehensive clear aligners were introduced in the market for the first time ever. And that's going to freak a lot of people out, right? So the promotions that you mentioned, were those specific to express type cases? Were they more specific to comprehensive? Any clarity you could give would be great.

    好的。接著 Joe,你可能已經在先前回答 Robert 的問題時提到過。如果這題重複我先道歉。但我認為這很重要,尤其大家都在關注促銷。所以你能否更清楚說明:你們本季所做的促銷,當大家同時聽到「促銷」這個詞、又看到市場上首次推出 2 或 3 款全方位(comprehensive)的透明矯正器時,這會讓很多人緊張,對吧?所以你提到的促銷,是針對 express 類型的病例嗎?還是更偏向針對 comprehensive?你能提供的任何釐清都會很有幫助。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes. Jon, to answer your question backwards is, these were comprehensive cases. From a competitive standpoint, look, we continue to monitor the competition in the marketplace. Ormco is still out in ANZ and not completely engaged. 3M, it's obviously hitting the marketplace in the United States and we see it. But these promotions were not geared towards trying to stop any competition that we're feeling right now, that wasn't the -- that wasn't the whole part of this promotional piece. Remember, third quarter's a big teen season. We make sure that we run the proper promotions going in there. This is a teen promotion and also adult promotion, too. Again, we're just trying some things in the sense of incentivizing the marketplace and it just happened to engage the upper tier of our Advantage Program rather than the lower tier that we had hoped. And these go on all the time, kind of under the radar screen, Jon. And we don't talk about them, this one in the sense of how it performed obviously, affecting ASP. We just have to give you clarity on it. But again, I want to reemphasize this is not based on anything competitively that we saw in the marketplace that we felt we had to move around.

    是的。Jon,倒過來回答你的問題,這些都是全面性的案例。從競爭的角度來看,我們持續監測市場上的競爭狀況。Ormco 仍在澳紐(ANZ)市場,但尚未完全投入。3M 很明顯正在美國市場發力,我們也看得到。但這些促銷並不是為了阻止我們目前感受到的任何競爭壓力;這——這並不是這次促銷活動的全部目的。請記得,第三季是青少年旺季。我們會確保在進入該季節時推出適當的促銷。這是一個青少年促銷,同時也有成人促銷。再說一次,我們只是嘗試一些作法,以激勵市場,而結果剛好帶動了我們 Advantage Program 的高階層級,而不是我們原本希望的低階層級。而這類活動一直都在進行,有點像在雷達下運作,Jon。我們通常不會談它們;但這一次因為其表現顯然影響了 ASP(平均售價),所以才提。我們只是需要讓你更清楚。但我再次強調,這並不是基於我們在市場上看到任何競爭因素、覺得必須採取行動才做的。

  • Operator

    Operator

  • Our next question comes on the line of Elizabeth Anderson from Evercore ISI.

    我們的下一個問題來自 Evercore ISI 的 Elizabeth Anderson。

  • Elizabeth Hammell Anderson - Associate

    Elizabeth Hammell Anderson - Associate

  • Speaking of what you were just talking about and sort of the engagement in the lower end of the market, how are you sort of thinking about what you're going to shift going forward? That would be my first question. And then could you sort of also talk about the typical GP path in that lower end customer? Do they start with lower-priced products and then sort of move up? Or is it -- do they sort of stay in that lower level product mix shift? Any further color on that would be really helpful.

    延續你剛才談到的、以及在市場低端的參與度(engagement)方面,你們接下來打算如何調整?這是我的第一個問題。另外,你能否也談談低端客戶典型的 GP(一般牙醫)導入路徑?他們是先從較低價的產品開始,然後再逐步往上升級嗎?還是——他們會一直停留在較低階的產品組合移轉上?如果能再多提供一些細節會很有幫助。

  • Shirley Stacy - VP of Corporate Communications & IR

    Shirley Stacy - VP of Corporate Communications & IR

  • Actually, can you repeat the first question? You're just kind of light on the volume. We couldn't hear the first part of your question.

    其實,你可以重複一下第一個問題嗎?你的音量有點小。我們沒聽到你問題的第一部分。

  • Elizabeth Hammell Anderson - Associate

    Elizabeth Hammell Anderson - Associate

  • Oh, sorry about that. Is that better?

    哦,不好意思。這樣有比較好嗎?

  • Shirley Stacy - VP of Corporate Communications & IR

    Shirley Stacy - VP of Corporate Communications & IR

  • Yes.

    有。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes.

    有。

  • Elizabeth Hammell Anderson - Associate

    Elizabeth Hammell Anderson - Associate

  • The first part of my question was, obviously, you said that you didn't get the engagement you were hoping for on the lower end of the market. So I was just wondering sort of what you had learned from that and sort of how you're thinking about that engagement with that segment of the market going forward?

    我問題的第一部分是,很明顯你們說在市場低端沒有得到你們原本希望的參與度。所以我想了解你們從中學到了什麼,以及接下來你們如何看待未來與該市場區隔的互動與參與?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes. On the lower end of the marketplace, it's just exactly how we target those incentives and how broad we make them, okay? This is broad across all of our Advantage tiers. In the future, we'll just have to focus on the lower tiers in that sense in order to encourage that piece. I mean, it's that simple kind of feedback. We thought it would be more of a balanced response across the tiers and it wasn't. And now on the GP, I think your second question had to do with GP doctors and how they get engaged. With iGo, as we start with iGo, it's a product, it's a midrange product that we position with GPs that allow them to be able to do certain kinds of movements that we think are relatively simple to learn and for doctors to really start off with the product line. And so as you see the iGo growth all around the world, that's predominantly what we call a midrange product that we are positioning with the GPs at the moment. Does that help?

    是的。在市場低端,關鍵就在於我們如何鎖定這些激勵措施,以及我們把範圍做得多廣,好的?這次是涵蓋我們所有 Advantage 的層級。未來,我們就必須在這個意義上更聚焦於較低層級,以鼓勵那一塊。我的意思是,回饋就是這麼簡單。我們原本以為各層級的反應會更均衡,但結果並不是。至於 GP,我想你的第二個問題是關於 GP 醫師如何被帶動參與。以 iGo 來說,我們從 iGo 開始;它是一個中階產品,我們把它定位給 GP,讓他們能做一些我們認為相對容易學習的移動類型,讓醫師能用這條產品線作為起步。因此你看到 iGo 在全球的成長,那主要就是我們所稱的中階產品,目前正定位給 GP。這樣有幫助嗎?

  • Elizabeth Hammell Anderson - Associate

    Elizabeth Hammell Anderson - Associate

  • Yes.

    有。

  • Shirley Stacy - VP of Corporate Communications & IR

    Shirley Stacy - VP of Corporate Communications & IR

  • Elizabeth, I'm just going to add one other thing, just in terms of what we're talking about with respect to ASP. The other part of the conversation has to do around the new Advantage Program this year. And then how that has additional tiers intended obviously to incentivize doctors to move up in tiers, and what we saw was the higher volume doctors moving up in tiers more than the lower tiers. So that's part of the impact as well.

    Elizabeth,我再補充一點,主要是就我們在談 ASP 的部分。對話的另一部分與今年新的 Advantage Program 有關。它新增了更多層級,顯然是要激勵醫師往更高層級提升;而我們看到的是,高量醫師往上升級的幅度比低層級更大。所以這也是影響的一部分。

  • Operator

    Operator

  • Our next question comes from the line of Steve Beuchaw from Morgan Stanley.

    我們的下一個問題來自 Morgan Stanley 的 Steve Beuchaw。

  • Stephen Christopher Beuchaw - Equity Analyst

    Stephen Christopher Beuchaw - Equity Analyst

  • I wonder if we could come back, Joe, to a point that you made earlier, maybe an intersection of a couple of points. I mean, you talked about how doctors are thinking about an evolving environment. I wonder, is there something in the environment that is changing the way that clinicians respond to promotions or product line efforts or to the Advantage Program? Is there something different about it this time? I ask the question because historically, the company has a lot of experience running these types of programs.

    Joe,我想回到你先前提到的一點,可能是幾個觀點的交會。你談到醫師如何看待一個正在演變的環境。我想問的是,是否有什麼環境因素正在改變臨床醫師對促銷、產品線推動或 Advantage Program 的反應方式?這次有什麼不同嗎?我之所以這麼問,是因為歷史上公司在執行這類計畫方面有很多經驗。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes. I don't think the market is conditioned any differently than it's been before. The biggest change we've seen in the market is really just the SDC in the United States marketplace. But that is a completely different segment. It's not through doctors' offices and obviously, that's not where the competition is right now. I think if you look at this, Steve, you'd think with this new Advantage Program we launched in North America in 2018, it just has a different series of brackets, different series of rewards and different kind of bonus levels. We haven't really engaged promotions around those things before so it was a little bit of a learning curve in the sense of how those brackets, as Shirley talked about yesterday, actually respond to these kinds of promotions. Don't look at this -- I think I can understand your questions and the previous questions about, is there some external aspect that's really driving those things? If there was an external some kind of catalyst in this sense, we'd tell you, okay? That's not why we do these things. We do these things to encourage customer stickiness, we do these things to figure out what really works in the marketplace. And there's -- look, I've never been in a business that has pricing elasticity curves like this business in it and you really have to study those. We launch promotions, we do them at certain prices. We see what the uptakes are and we learn from those things. We're just launching this -- again, it's a different type of an advantage structured program and these tiers are different and this take-up was completely different than what we've seen before.

    是的。我不認為市場的「被訓練程度」跟以前有什麼不同。我們在市場上看到最大的變化,主要就是美國市場的 SDC。但那是完全不同的區隔。它不是透過醫師診所,顯然目前的競爭也不在那裡。Steve,我想如果你看這件事,會覺得我們在 2018 年於北美推出的新 Advantage Program,確實有不同的一系列級距、不同的一系列獎勵,以及不同的獎金層級。我們以前沒有真的圍繞這些內容去做促銷,所以在某種程度上有一個學習曲線:正如 Shirley 昨天提到的,這些級距實際上如何回應這類促銷。不要把這件事——我理解你以及前面問題在問:是否有某個外部因素真的在驅動這些事情?如果在這個意義上真有某種外部催化因素,我們會告訴你,好嗎?但這不是我們做這些事的原因。我們做這些事是為了提升客戶黏著度,也是為了找出市場上真正有效的方法。而且——你看,我從沒待過一個像這個產業一樣具有這種價格彈性曲線的生意,你必須研究那些曲線。我們推出促銷,在特定價格點執行。我們觀察採用率,並從中學習。我們只是推出——再說一次,這是一種不同類型、以 Advantage 架構的計畫;這些層級不同,而這次的採用情況也與我們過去看到的完全不同。

  • Stephen Christopher Beuchaw - Equity Analyst

    Stephen Christopher Beuchaw - Equity Analyst

  • Okay, got it. And then just a follow-up on your point about SDC. I think I know the answer to this. But your view is still that any overlap between SDC cases and Align cases is low single-digit percentage-wise. Is that still correct?

    好的,了解。另外針對你提到 SDC 的部分再追問一下。我想我知道答案。但你的看法仍然是,SDC 案例與 Align 案例之間的重疊比例很低,以百分比來看是個位數的低段。這仍然正確嗎?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • I think we've always said it's about when we -- back when we were actually comparing data with these guys, back before our lawsuit. And it was about a 10% overlap is what we saw overall. We don't have any information that would change that at all at this point.

    我想我們一直都說,這取決於我們——回到我們實際上還在和這些人比對資料的時候,也就是在我們提起訴訟之前。而我們當時看到的整體重疊率大約是 10%。截至目前,我們沒有任何資訊會改變這個看法。

  • Operator

    Operator

  • Our next question comes from the line of John Kreger from William Blair.

    下一個問題來自 William Blair 的 John Kreger。

  • John Charles Kreger - Partner & Healthcare Services Analyst

    John Charles Kreger - Partner & Healthcare Services Analyst

  • Joe, any update on the timing for mandibular advancement in the U.S. or the palate expansion product that you talked about at Investor Day?

    Joe,關於下顎前移(mandibular advancement)在美國的推出時程,或是你在投資人日提到的上顎擴弓產品(palate expansion product),有沒有最新進度?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes. John, we're expecting in the fourth quarter, is what we said all along. Our communications with the FDA have been nothing bad or anything that would suggest that we're not on course. So I'd just say, we're still sticking to our plan of being able to launch this product in the fourth quarter in the United States.

    有。John,我們一直以來的說法都是預期在第四季。我們與 FDA 的溝通沒有任何不利訊息,也沒有任何跡象顯示我們不在既定進度上。所以我只能說,我們仍然會依照計畫,在美國於第四季推出這項產品。

  • John Charles Kreger - Partner & Healthcare Services Analyst

    John Charles Kreger - Partner & Healthcare Services Analyst

  • Okay. And then how about the palate expander product?

    好的。那上顎擴弓產品呢?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Palate expander, we're still working through that. When you think about it, our Invisalign First product is a palate expansion product but it's not a rapid palate expansion product. So we're digging into that 6 to 8-year, 9-year marketplace with Invisalign First. We're still working through -- in fact, I went through it this morning with the team. We're still working through the rapid palate expander. And we'll give you an update on that as there's more to talk about. We're still thinking that's rallying in 2019 like we indicated at the most recent investors conference.

    上顎擴弓方面,我們仍在推進中。你如果這樣想,我們的 Invisalign First 產品本身就是一種上顎擴弓產品,但它不是快速上顎擴弓(rapid palate expansion)產品。因此我們正透過 Invisalign First 深入耕耘 6 到 8 歲、9 歲的市場。我們仍在處理——事實上我今天早上才和團隊一起檢視過。我們仍在推進快速上顎擴弓器。等有更多內容可談時,我們會再向你更新。我們仍然認為它會在 2019 年如我們在最近一次投資人會議所指出的那樣逐步到位。

  • John Charles Kreger - Partner & Healthcare Services Analyst

    John Charles Kreger - Partner & Healthcare Services Analyst

  • Okay. And then maybe just, John, any kind of key puts or takes you want to call out as we start thinking more about the outlook for '19? I assume FX will be a bigger factor in the coming year?

    好的。那再請問一下,John,當我們開始更深入思考 2019 年展望時,有沒有什麼關鍵的利多或利空你想特別點出?我猜匯率(FX)在明年會是更大的因素?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Yes. We're not giving the 2019 guidance as you know, John. But FX is a piece of it, we call it out. It is what it is. And then everything else is on our operational performance, but we'll give a good update on 2019 at the next call.

    是的。如你所知,John,我們不會提供 2019 年的指引。但匯率確實是其中一部分,我們也會特別提出。它就是它本來的樣子。其他部分則取決於我們的營運表現;我們會在下一次電話會議中對 2019 年提供更完整的更新。

  • Operator

    Operator

  • Our next question comes from the line of Matthew O'Brien from Piper Jaffray.

    下一個問題來自 Piper Jaffray 的 Matthew O'Brien。

  • Matthew Oliver O'Brien - MD and Senior Research Analyst

    Matthew Oliver O'Brien - MD and Senior Research Analyst

  • So if I look at your slides that you provided, Slide 30 specifically. You can see a step down, Q3 to Q4, on the pricing side both worldwide and internationally. Were you running some kind of program similar to this back Advantage and we saw recovery over the next several quarters? Is that something kind of like what we should expect this time around?

    如果我看你們提供的投影片,特別是第 30 頁。可以看到在定價面,無論是全球或國際市場,從第三季到第四季都有一個下滑。你們是否在執行某種類似於之前 Advantage 時期的方案,而我們在接下來幾季看到回升?這次我們也應該期待類似的情況嗎?

  • Shirley Stacy - VP of Corporate Communications & IR

    Shirley Stacy - VP of Corporate Communications & IR

  • FX.

    匯率(FX)。

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Yes. I mean, and what we see, Matt, and that comes through some of those slides and trends is FX effect. So there's -- if there's foreign exchange that comes through there, it shows up as well. So some of that's -- especially when you look on the international side, you could see some of the FX there.

    是的。我的意思是,Matt,我們看到的情況——而且在那些投影片與趨勢中也反映出來——是匯率影響。所以如果有外匯因素反映在那裡,也會呈現出來。因此其中一部分——尤其你看國際市場那一側——你會看到一些匯率的影響。

  • Matthew Oliver O'Brien - MD and Senior Research Analyst

    Matthew Oliver O'Brien - MD and Senior Research Analyst

  • All right. So just to push a little bit further on that question specifically though. The moderation that you should get from the promotion going away and maybe some more mix benefits going forward, this should be kind of a low watermark, maybe here in Q3 for the ASPs with gradual increase over the next several quarters. Is that fair?

    了解。不過就這個問題我再追問一下。隨著促銷活動結束,你們應該會看到一些回升,再加上未來可能有更多產品組合(mix)帶來的好處;因此這裡(也許在第三季)應該會是 ASP 的低點,接下來幾季會逐步上升。這樣理解合理嗎?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Yes. I think what we're expecting is kind of the Q4 ASPs, that we're kind of calling, should be that low point. And that's how you should think about things going forward.

    是的。我想我們的預期是,我們所提到的第四季 ASP 大概會是那個低點。你之後可以用這樣的方式來看待未來的走勢。

  • Matthew Oliver O'Brien - MD and Senior Research Analyst

    Matthew Oliver O'Brien - MD and Senior Research Analyst

  • Okay. And then as the follow-up question and actually to talk about something positive in the quarter, even though there was a lot positive. On the scanner side specifically, can you parse out a little bit where that performance came from? Because that should be a pretty good leading indicator for the business going forward, DSOs, international, et cetera. Would you mind just providing a little more color there?

    好的。接著作為追問,也想談談本季一些正面的事情——雖然其實有很多正面表現。就掃描器(scanner)業務而言,你能否稍微拆解一下這個表現主要來自哪些因素?因為這應該是未來業務相當好的領先指標,例如 DSO、國際市場等等。你介意多提供一些細節嗎?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes, Matt. It's Joe. When we look at it and we really -- every region we had a lot of strength in iTero. I'll start with we have now major penetration into China and great uptake there. Last year, we were approved in Japan and that's been good, too. So really all up and down. Asia, it's been strong. In North America, it's been strong across our individual doctor base, but also, as you mentioned, the DSOs have been very strong also. And then also in the quarter, we do see increasing momentum with iTero scanners over in Europe, too, which is our most difficult competitive market. We have good momentum there, too. The launch of the Flex product line and iTero 2 were really great launches. Customers love the product, too. So the responses have been terrific. So everything has been working extremely well with that business. But remember, that's just a wonderful footprint for us for future Invisalign business once we have those scanners in place.

    好的,Matt。我是 Joe。我們回頭看時,幾乎每個區域的 iTero 都展現出很強的動能。我先從中國說起:我們現在在中國的滲透率已經很高,而且採用情況非常好。去年我們在日本獲得核准,那邊的表現也不錯。所以整體來看,上上下下都很強。在亞洲一直很強。在北美,我們在個別醫師客戶基礎上表現強勁;同時如你提到的,DSO 端也非常強。另外,本季我們也看到 iTero 掃描器在歐洲的動能持續提升,而歐洲是我們競爭最激烈、也最困難的市場。我們在那裡也有不錯的動能。Flex 產品線與 iTero 2 的推出都非常成功。客戶也很喜歡這些產品。因此市場回饋非常好。所以這項業務各方面都運作得非常順利。但請記得,這些掃描器一旦部署到位,對我們未來的 Invisalign 業務而言,就是一個非常好的基礎版圖。

  • Operator

    Operator

  • Our next question comes from the line of Richard Newitter with Leerink Partners.

    下一個問題來自 Leerink Partners 的 Richard Newitter。

  • Richard S. Newitter - MD, Medical Supplies & Devices and Senior Analyst

    Richard S. Newitter - MD, Medical Supplies & Devices and Senior Analyst

  • I wanted to just clarify. I think you had you said you're still expecting mandibular expansion -- I'm sorry, the mandibular product in the fourth quarter, best of your abilities to predict the FDA. Is it right that, that's not factored into your Invisalign case volume guidance or your 4Q guidance?

    我想再確認一下。我記得你說你們仍預期下顎擴張——抱歉,是下顎產品——會在第四季推出,當然是在你們能夠預測 FDA 的範圍內。我理解正確嗎:這並沒有納入你們 Invisalign 病例量指引或第四季指引之中?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes. We don't factor that in. But honestly, within 1 quarter of the launch of that, we wouldn't expect anything material, Richard, to report in that sense and that's not anything to do with mandibular advancement. It's just the way things work around here in the sense of doctors will try this, they'll do a few cases, they'll get used to it. And then as we move into 2019, we can give you some idea of what we think mandibular advancement in the United States uptake would be.

    是的。我們沒有把它納入。但老實說,在該產品上市後的 1 個季度內,我們也不預期會有任何重大、可報告的影響,Richard;而這點並不是因為下顎前移本身。只是我們這裡的運作方式通常是:醫師會先試用,做幾個病例,熟悉之後才會逐步增加。等我們進入 2019 年,我們可以再給你一些我們對下顎前移在美國採用情況的看法。

  • Richard S. Newitter - MD, Medical Supplies & Devices and Senior Analyst

    Richard S. Newitter - MD, Medical Supplies & Devices and Senior Analyst

  • Okay. That's helpful. And just maybe one other one. I noticed that the percentage of cases submitted with the digital scanner in the Americas was flat. It's been increasing almost every quarter for quite some time. I'm just wondering if that's somehow linked to some of the anomalies that we saw around trends with ASPs or if there's any other explanation there?

    好的。這很有幫助。再問一個。我注意到在美洲地區,使用數位掃描器提交的病例占比持平。這個比例在相當長一段時間幾乎每季都在上升。我想知道這是否與我們在 ASP 趨勢上看到的一些異常有關,或是還有其他解釋?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • No, Richard. There's no correlation with the ASP side. If you remember last year, we ceased allowing 3Shape to be able to submit scans. And so those doctors, they'll have to go back to PVS impressions. And we think that's pretty much what drove that. Obviously, our scanner sales have been really strong in United States. So we think that's just basically a resubmittal because of the situation we have with 3Shape right now.

    不,Richard。這和ASP端沒有相關性。如果你還記得去年,我們已停止允許3Shape提交掃描。因此那些醫師就必須回到PVS印模。而我們認為這基本上就是造成那個情況的原因。顯然,我們的掃描器在美國的銷售一直非常強勁。所以我們認為,這基本上只是因為我們目前與3Shape的狀況而產生的重新提交。

  • Richard S. Newitter - MD, Medical Supplies & Devices and Senior Analyst

    Richard S. Newitter - MD, Medical Supplies & Devices and Senior Analyst

  • Okay. And then maybe just one last one. You said that you didn't get an expected kind of reaction in the marketplace from kind of the promotions across kind of both parts of the market, complex and simple. I guess, what's your hypothesis as to why it didn't work on the low end of the market? Or do you have kind of a running assumption as to what maybe you got wrong or why it didn't work?

    好的。那最後再問一個。你提到你沒有在市場上看到預期的反應,來自於橫跨市場兩端(複雜與簡單)的促銷活動。我想問,你的假設是什麼,為什麼它在市場的低端沒有奏效?或者你是否有一個持續的假設,認為可能是哪裡做錯了或為什麼沒有奏效?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes. I think, Richard, first of all, it's not low end, it's low tier. So we have an Advantage Program. That Advantage Program has several tiers. It starts at bronze, it goes all the way up to double diamond, okay? And so when we talk about that, these are, still broadly, they're comprehensive cases, okay? When you put these promotions in place, you want to make sure you're sensitive into the sense of who you're incentivizing across these brackets, right? What we're saying is we didn't have strong enough incentives on the, what we'd say the lower end of our Advantage tier program. And obviously, that will be the change we would make going forward. Makes sense, Richard?

    是的。我想,Richard,首先,那不是低端,是低層級。我們有一個Advantage Program(優勢方案)。這個Advantage Program有好幾個層級。從青銅開始,一直到雙鑽,對吧?所以當我們談到這個時,這些案例整體而言仍然是綜合性案例,好嗎?當你推出這些促銷時,你要確保你對於在這些區間中要激勵的是哪些對象保持敏感,對吧?我們的意思是,在我們Advantage分級方案中較低端的層級,我們提供的誘因不夠強。而顯然,這將是我們未來要做的調整。這樣說合理嗎,Richard?

  • Richard S. Newitter - MD, Medical Supplies & Devices and Senior Analyst

    Richard S. Newitter - MD, Medical Supplies & Devices and Senior Analyst

  • Yes.

    是的。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • I thought we lost you.

    我還以為我們失去你的連線了。

  • Operator

    Operator

  • Our next question comes from the line of Erin Wright from Credit Suisse.

    我們的下一個問題來自Credit Suisse的Erin Wright。

  • Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst

    Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst

  • I won't ask about ASPs. But the Invisalign Experience locations, could you provide any sort of new metrics around in terms of conversion rate or traction or any sort of key performance kind of metrics there? And how will the economics work for the doctor-led Invisalign Experience locations with the rebranding and all?

    我不會問ASP。但關於Invisalign Experience據點,你能否提供任何新的指標,例如轉換率、推進情況或任何關鍵績效指標?另外,隨著重新品牌化,醫師主導的Invisalign Experience據點,其經濟模式會如何運作?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Erin, we haven't given any statistics yet on our experience enters. And we only had 4. And now, we're expanding the other 8 stores right now. As we move into 2019, we'll be more transparent with that information. The doctors can engage in several ways. If the doctors are actually engaged at the store. These products have a certain premium assigned to them because we actually attract the patients and send the scans to the doctors or whatever. So depending on what it is, signature, signature plus or deluxe, there's obviously a lab fee for the aligners but there's also a certain fee for those types of products. And then we're talking about the halo effect, too. The halo effect, sometimes it's the doctors who aren't even associated with the program at all. There's still -- we're still seeing a significant increase in Invisalign sales with those doctors just because of just the raising the awareness of Invisalign and doctors in that specific geographical area. And those are areas that are anywhere between 10, 25, up to 50 miles, we start to see that kind of response.

    Erin,我們目前還沒有公布任何關於我們Experience中心的統計數據。而且我們當時只有4家。現在我們正在擴展另外8家門市。隨著我們進入2019年,我們會更透明地提供這些資訊。醫師可以用幾種方式參與。如果醫師實際在門市參與。這些產品會被賦予一定的溢價,因為我們實際上會吸引患者,並把掃描資料送給醫師或類似的流程。所以視產品類型而定,像是signature、signature plus或deluxe,除了矯正器的技工費之外,這些類型的產品也會有一定的費用。然後我們也在談光環效應(halo effect)。光環效應有時候來自於那些根本沒有參與該方案的醫師。我們仍然看到這些醫師的Invisalign銷售顯著增加,原因只是因為在特定地理區域內提升了Invisalign以及醫師的知名度。而這些區域大約介於10、25到最多50英里,我們開始看到那樣的反應。

  • Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst

    Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst

  • Okay, great. And then you've previously alluded to financing initiatives for customers. That seems to make sense here but I don't really hear you speak much about it. I guess, where does that stand today on that effort and that remains purely a third-party relationship today?

    好的,很好。另外,你之前曾提到針對客戶的融資方案。這在這裡看起來很合理,但我沒有聽到你們談很多。我想問,這項工作的目前進展如何?而且今天仍然完全是第三方合作關係嗎?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Hi, Erin. Yes, this is John. Yes, the financing, it continues. It's primarily in the U.S. and it's something where it's financing, that's not on our balance sheets, third party company that we work with. And really, we're just trying to get -- find the easier ways for our end consumers to be able to use Invisalign and make things easier for them. So we continue to do it. It's part of the conversion that we try to use. And it's been rolled out across the U.S. for a few quarters now.

    嗨,Erin。是的,我是John。是的,融資方案仍在持續。主要是在美國,且這是一種不會列在我們資產負債表上的融資安排,我們與第三方公司合作。而我們真正想做的是——找到更簡單的方法,讓終端消費者能夠使用Invisalign,讓他們更方便。所以我們會持續推動。這是我們用來提升轉換的一部分工具。而且它已在美國推行了好幾個季度。

  • Operator

    Operator

  • Our next question comes from line of Steven Valiquette from Barclays.

    我們的下一個問題來自Barclays的Steven Valiquette。

  • Steven J. James Valiquette - Research Analyst

    Steven J. James Valiquette - Research Analyst

  • So I guess for the 35% case growth in the quarter, which obviously accelerated pretty nicely. Just curious if there's any color on how much of the volume growth was maybe tied to what we'll call the overly enhanced promotional activity or are you more of the mindset that maybe you would've had essentially the same case volume growth overall if there were no alterations to the loyalty program?

    所以我想問,本季病例量成長35%,顯然加速得相當不錯。想請教是否能提供一些說明:這些量的成長有多少可能與我們所稱的「過度強化」促銷活動有關?或者你們比較傾向認為,即使忠誠計畫沒有任何調整,整體病例量成長基本上也會差不多?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Steve, we can't nail it exactly. But we could tell you it's 1% to 2% on the North America volume.

    Steve,我們無法精確釘出來。但我們可以告訴你,在北美的量大約是1%到2%。

  • Steven J. James Valiquette - Research Analyst

    Steven J. James Valiquette - Research Analyst

  • Okay. And one other quick one. Again, if you're suddenly off on where you want to be on your ASPs because of this activity, just kind of thinking out loud without giving anything away for next year, just curious if you also think you could potentially increase list prices maybe a bit more than normal to get you where you want to be in ASPs for 2019, just as another lever that you could pull if you wanted to when thinking about optimizing price?

    好的。再一個很快的問題。同樣地,如果因為這些活動導致你們的ASP偏離你們想要的位置,我只是把想法說出來、不涉及明年任何細節:想請教你們是否也認為,為了讓2019年的ASP回到你們想要的水準,你們可能會把牌價上調得比平常多一些,作為你們在思考最佳化定價時可以運用的另一個槓桿?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Well, we don't comment on price going into the year. We just never did that, Steve. But we have raised price every year in the last 3 years. Obviously, we raised price in this quarter, too. And it's been part of our strategy. It's part -- it fuels a lot of the things we would do when we talk about Invisalign Experience and our marketing campaign in driving customers and doctors. Also, all the technology we invest in too. So it's been a pretty large part of our strategic plan. But I don't want to comment on 2019 in advance.

    嗯,我們不會在年度開始前評論價格。我們一向不這麼做,Steve。但在過去3年裡,我們每年都有調漲價格。顯然,我們在本季也調漲了價格。而這一直是我們策略的一部分。這也是——當我們談到Invisalign Experience以及我們的行銷活動、推動客戶與醫師時,許多我們要做的事情的資金來源之一。也包括我們投入的所有技術。所以這一直是我們策略計畫中相當重要的一部分。但我不想提前評論2019年。

  • Operator

    Operator

  • Our next question comes from the line of Jeff Johnson from Robert Baird & Company.

    我們的下一個問題來自Robert Baird & Company的Jeff Johnson。

  • Jeffrey D. Johnson - Senior Research Analyst

    Jeffrey D. Johnson - Senior Research Analyst

  • Joe, so let me start just on the Invisalign Experience. It sounds like you're moving that into some private practitioners or some other offices here in the fourth quarter. Any discussions on moving that into the DSO channel where you can almost supercharge that and really get into 600 to 800 offices at a time? And in those cases, I think you alluded to it, Joe, a little bit in your comments just a second ago. But my sense, at least from the conversations I've had, is that the gross margins are actually accretive in cases that come through that kind of channel because you're kind of doing some of the work to get the patient into that office. Is that a fair way to look at that?

    Joe,那我先從Invisalign Experience開始。聽起來你們在第四季會把它推進到一些私人診所或其他辦公室。有沒有討論過把它推進到DSO通路,這樣你們幾乎可以把它「加速放大」,一次就進入600到800家診所?而在那些情況下,我想你剛剛也稍微提到,Joe。但至少從我談過的內容來看,透過那種通路進來的案例,毛利其實是增厚的,因為你們某種程度上是在做一部分工作,把患者導入那家診所。這樣看是否合理?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes. Jeff, it's a really fair way to look at it. I mean, we talked about Aspen in the last quarter. I mean, the whole idea of the Aspen piece and their uptake of iTero scanners was to put what we used to call a store in store, or we now call it Invisalign Experience in the doctors' offices within Aspen. And part of what we've done in the store is that we've created, obviously, consumer material. We've created a lot of things. From a customer engagement standpoint, turn customers into patients. We've put those in place and we'll be able to employ in those DSO stores, too. So that's been a big part of our strategy and it's one of the reasons you see such a big uptake in the DSOs that we've been selling to and reporting.

    是的。Jeff,這樣看待確實很公平。我的意思是,我們在上一季談過 Aspen。我的意思是,Aspen 這一塊以及他們採用 iTero 掃描儀的整體構想,是把我們過去稱為「店中店」(store in store)的模式,或我們現在稱為「Invisalign 體驗」(Invisalign Experience),放到 Aspen 體系內醫師的診所裡。而我們在這個「店」裡所做的一部分,是我們顯然製作了面向消費者的素材。我們也做了很多事情。從客戶互動的角度,把消費者轉化為病患。我們已經把這些都落地,並且也能在那些 DSO 的「店」裡運用。所以這一直是我們策略的重要部分,也是你看到我們所銷售並揭露的 DSO 客戶採用率如此高的原因之一。

  • Jeffrey D. Johnson - Senior Research Analyst

    Jeffrey D. Johnson - Senior Research Analyst

  • Yes. Fair enough. And then again, there hasn't been enough ASP questions here tonight but I just want to understand, John, your comments. You get some of the promotional activities right sized in the fourth quarter, currency probably is a little bit bigger of an impact going forward. So fourth quarter, you would expect ASP to be down sequentially a bit versus 3Q, is that right? And then we kind of see a recovery throughout 2019 or at least a little bit trending up in 2019 as some of those currency headwinds in the back half come off and maybe some of the promotional activity headwinds do as well?

    是的。可以理解。然後再一次,今晚關於 ASP 的問題不多,但我只是想理解一下,John,你的評論。你們在第四季把部分促銷活動調整到合適規模,而往後看匯率可能會帶來更大的影響。所以在第四季,你會預期 ASP 相較於第三季會按季略為下滑,對嗎?然後我們在 2019 年會看到回升,或至少在 2019 年略為走升,因為下半年那些匯率逆風消退,或許部分促銷活動的逆風也會減輕?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Jeff. What we would see is you're right. On the FX, you see it come down a little bit from an ASP standpoint into the -- in the fourth quarter. But then from the fourth quarter, we expect it to be about flat, just given the mix and other things that we've talked about in terms of what we see in the business.

    Jeff。我們看到的情況是,你說得對。在外匯(FX)方面,從 ASP 的角度來看,第四季會略微下來一些。但從第四季之後,我們預期大致持平,主要是考量產品組合以及我們先前談到的其他因素,也就是我們在業務中所看到的情況。

  • Jeffrey D. Johnson - Senior Research Analyst

    Jeffrey D. Johnson - Senior Research Analyst

  • Okay. And just to clarify that. So whatever our fourth quarter ASP, whatever that ends up, that you would expect holding flat then moving throughout 2019 sequentially?

    好的。我再確認一下。所以不論我們第四季的 ASP 最終是多少,你們預期在 2019 年接下來各季會維持持平、按季持平,是嗎?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Yes, that's how we would look at it.

    是的,我們就是這樣看。

  • Operator

    Operator

  • Our next question comes from the line of Ravi Misra from Berenberg Capital Markets.

    我們的下一個問題來自 Berenberg Capital Markets 的 Ravi Misra。

  • Ravi Misra - Analyst

    Ravi Misra - Analyst

  • Just a couple based on the margin outlook for the business. So just working through that flat pricing outlook, how do we think about the gross margin implication on the aligner business? I mean, you have these plants coming online. Is it similar type of kind of ramp that we look at a step down from 3Q in the aligner gross model and that kind of remains flat or slightly increases going forward into '19? And then just a question on the marketing strategy, as kind of Raph steps aside. You have a number of new programs going on here. You have a new marketing leader coming in. You have an orthodontic summit in a month. How do you kind of, like, look at your dental segment in your customer base, your orthodontist here? Are we in a world where you're trying to get greater productivity from your top dentists and let the less productive guys, I guess to call it, less of a focus on that or is there room for everyone here? How are you looking to approach that?

    我有幾個問題,主要基於公司毛利率展望。在這個價格持平的展望下,我們該如何看待隱形矯治器(aligner)業務對毛利率的影響?我的意思是,你們有這些工廠陸續投產。這是否類似我們看到的那種爬坡型態:隱形矯治器毛利率模型在第三季之後出現一個台階式下滑,之後維持持平或在 2019 年略有提升?另外一個是行銷策略的問題,因為 Raph 退居一旁。你們現在有不少新計畫在進行。你們也會有新的行銷主管加入。一個月後還有一場矯正高峰會。你們如何看待牙科這個客群分層、你們的客戶基礎、以及你們這裡的矯正醫師?我們是否處在一個情境:你們想從頂尖牙醫(或頂尖矯正醫師)身上取得更高生產力,而對那些生產力較低的(姑且這麼說)就比較不聚焦?還是說每個人都有空間?你們打算如何切入?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Ravi, I'll take the gross margin question, yes. As we said, coming online with some of the manufacturing adds a certain amount of cost that we need some of the volume now to be able to spread those costs over. So we guided in Q4 to reflect that. And then as we get more efficient related to that manufacturing, both the manufacturing and the treatment planning that we have kind of globally, we'll start to see some of the efficiencies related to that manufacturing and treatment planning that will affect our gross margins.

    Ravi,我來回答毛利率的問題,是的。如同我們所說,部分製造產能上線會增加一定的成本,而我們現在需要一定的出貨量,才能把這些成本攤提開來。所以我們在第四季的指引已反映這點。接著,隨著我們在製造端的效率提升,以及我們在全球的製造與治療計畫(treatment planning)流程效率提升,我們會開始看到與製造與治療計畫相關的效率改善,進而影響我們的毛利率。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • And Ravi, it's Joe. Your question on the segment and top dentists versus -- or top orthos versus lower brackets. I'd just end up by saying that there's room for everyone. You have to segment this market always between general dentistry, as we call it, GPs, and also orthodontists. But when we talked about it at Investors Day, we see a market that we used to measure as 12 million case starts a year as potentially 300 million. But what we specifically talk about with our doctors, particularly on the ortho side, is this is a massive, what we call, analog to digital conversion, right? If you really want to get the productivity of a digital-based orthodontic system that ends up in plastic and that's what our process is, is you really have to do predominantly, a majority of your business has to be in digital. And those doctors that walk forward that want to go through that journey with us, we have a number of programs to take them through from financing to how you encourage more consumers, how you set up your practice, all those things, so you can make it as efficient as possible. On the general dentistry side, we often work from a restorative standpoint to make sure that we can work within those restorative workflows and make sure that it's profitable for those docs and they understand how to use these things. Ravi, one thing I want to make certain and it's just -- maybe it's just me being overly sensitive. Don't take Raph's announcement in any way as any indication that he had some responsibility for this promotional aspect for what went on. Raph's been tremendous for us after running our international business, coming into running marketing and strategic development and also business development. He's been critical to this business. This is not some kind of smoke and mirrors. This is Raph making a decision from a family standpoint that he's had issues with, that has to deal with right now. And we support Raph in that from a family standpoint. This has nothing to do with him.

    Ravi,我是 Joe。你問到客群分層,以及頂尖牙醫(或頂尖矯正醫師)相對於較低層級的部分。我最後想說的是:每個人都有空間。你必須一直把這個市場分成我們所說的一般牙科(general dentistry),也就是 GP,以及矯正專科醫師。但如同我們在投資人日所談,我們過去衡量的市場是一年 1,200 萬個起始病例(case starts),而它的潛在規模可能是 3 億。不過我們與醫師溝通時,特別是在矯正端,我們具體談的是:這是一個巨大的、我們所稱的「類比到數位」轉換,對吧?如果你真的想要取得以數位為基礎、最終產出為塑料(也就是我們的流程)的矯正系統的生產力,那你的業務就必須以數位為主,佔大多數。而對於那些願意往前走、想和我們一起走這段旅程的醫師,我們有許多計畫帶他們走過去,從融資到如何吸引更多消費者、如何設置診所、以及所有這些事情,讓你能盡可能高效率地運作。在一般牙科端,我們常常從修復(restorative)的角度合作,確保我們能融入那些修復工作流程,並確保對那些醫師而言是有利可圖的,而且他們也了解如何使用這些工具。Ravi,有一點我想確認,而且這只是——也許只是我過於敏感。不要把 Raph 的公告以任何方式解讀為:他對這次促銷面向所發生的事情負有某種責任。Raph 在我們這裡一直非常出色,先是負責我們的國際業務,之後接手行銷與策略發展,也負責業務發展。他對這家公司至關重要。這不是什麼障眼法。這是 Raph 從家庭角度做出的決定,他有一些家庭方面的狀況,現在必須去處理。我們也從家庭的角度支持 Raph。這與他無關。

  • Operator

    Operator

  • Our next question comes from the line of Michael Ryskin from Bank of America Merrill Lynch.

    我們的下一個問題來自美國銀行美林(Bank of America Merrill Lynch)的 Michael Ryskin。

  • Michael Leonidovich Ryskin - Associate

    Michael Leonidovich Ryskin - Associate

  • A lot of the questions have been taken, but I just want to follow up on a couple of points. One is, are you getting any sense that the pretty substantial price difference in the quarter, the discounts, are they being passed on to customers by the dentists? I know it's tough to measure those channels sometimes and it's aggregated. But are you getting any sense if the dentist themselves are being squeezed on pricing by the end customer and they have to do something to adjust?

    很多問題都已經被問過了,但我想就幾點再追問一下。第一個是,你們是否有任何跡象顯示:本季相當顯著的價差、這些折扣,是否被牙醫轉嫁給終端客戶?我知道有時候這些通路很難衡量,而且數據是彙總的。但你們是否感覺到牙醫本身在定價上被終端客戶擠壓,因此他們必須做些調整?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • We don't have any data, Michael, to hold up with that. I'd say remember, there's a million points of light in this business, too, because there's so many doctors in overall involved. But I don't feel this has to do with having these promotions actually in some way and have that passed on to consumers. It's just not the feedback we get or what we think is going on.

    Michael,我們沒有任何數據可以用來佐證這件事。我會說,請記得,這個業務也有「百萬個光點」,因為整體參與的醫師數量非常多。但我不覺得這與我們做這些促銷、並以某種方式被轉嫁給消費者有關。這不是我們收到的回饋,也不是我們認為正在發生的情況。

  • Michael Leonidovich Ryskin - Associate

    Michael Leonidovich Ryskin - Associate

  • All right. And then a follow-up just real quick. On the DSOs, I think you mentioned 40% growth in the quarter. As a customer group thing, is there -- and the mix is shifting, still small part of the overall business, but is there anything that's different there in terms of how much price you're able to get with those customers versus some of the stand-alone docs?

    好的。接著再追問一個很快的問題。關於 DSO,我想你提到本季成長 40%。就客戶群的角度來看,是否有——而且組合正在轉移,雖然仍只占整體業務的一小部分——在你能從這些客戶取得的價格,相較於一些獨立診所醫師,有沒有什麼不同?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • From a DSO standpoint, obviously, these are large contracts we put in place. And there's significant price discounts in the sense for the volumes that the DSOs offer. So when we talk about mix, there's a certain amount of mix associated with DSOs. When you see these kind of growth rates, 40%, it's obviously some aspect of the mix that we're talking about. So when you think about that, too, Michael, is that we don't have to spend as much OpEx on the DSOs. And it's really important to understand. A lot of them, since they are general dentists, they use their own patients to generate their demand. The normal GP dentist would have 1,500 to 2,000 patients per office. We can help them mine those patients and understand which ones would want orthodontic treatment or could stand for orthodontic treatment or not. We don't have to have the amount of sales coverage that we have with individual doctors. So you're going to have a lower overall ASP in those businesses. But we feel that from an OpEx standpoint, we're not spending as much money, too. So from a gross margin standpoint, it's still positive for us.

    從 DSO 的角度來看,顯然這些是我們簽訂的大型合約。而且就 DSO 提供的量而言,價格折扣幅度相當大。所以當我們談到組合時,會有一部分的組合是與 DSO 相關。當你看到這種 40% 的成長率時,顯然我們談的就是組合中的某個面向。所以你也要這樣想,Michael,我們在 DSO 上不需要花那麼多營運費用(OpEx)。而這點非常重要,需要理解。很多 DSO 因為是一般牙醫,他們用自己的病患來產生需求。一般的 GP 牙醫每個診所大約有 1,500 到 2,000 名病患。我們可以協助他們挖掘這些病患,並了解哪些人想要做矯正治療、哪些人適合做矯正治療或不適合。我們不需要像面對個別醫師那樣投入那麼多的銷售覆蓋。因此在那些業務中,你會看到整體 ASP 較低。但我們也認為,從 OpEx 的角度來看,我們同樣沒有花那麼多錢。所以從毛利率的角度來看,對我們仍然是正面的。

  • Operator

    Operator

  • Our next question comes from the line of Chris Cooley from Stephens.

    我們的下一個問題來自 Stephens 的 Chris Cooley。

  • Christopher Cook Cooley - MD

    Christopher Cook Cooley - MD

  • Just 2 quick ones for me. Maybe, Joe, to start with. You mentioned in one of the prior questions, price elasticity curves for the market. Could maybe just give us your views, as the market continues to evolve, what level of margin you think that your higher echelon volume providers expect to maintain and maybe how that differs versus the lower tier provider as these markets evolve, just in terms of profitability by caseload? And then just from a clarification standpoint, John, if I'm doing the math right, just kind of doing the puts and takes on the one-timers there on the tax right in the quarter, am I right and that it's about $0.05 to the positive when we look at the net effect there for the 3Q?

    我這邊有兩個很快的問題。也許先請 Joe 回答。你在前面某個問題中提到市場的價格彈性曲線。能否談談你的看法:隨著市場持續演變,你認為你們較高階的高量提供者期望維持什麼水準的利潤率?以及隨著市場演變,這與較低層級提供者相比有何不同——就每個案例量的獲利能力而言?另外再澄清一下,John,如果我算得沒錯,就本季稅務那邊一次性項目的加減影響來看,我是否可以理解為,若看 3Q 的淨影響,大約是正向 $0.05?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Yes. Just on the tax. We just gave kind of the highlights of the overall that affected tax. And we had guided 21% and it ended up at 19.5%. So you can pretty much say that it's -- 1.5 of our tax was a few things that came in a little bit favorable compared to what we guide. But those 2 were just kind of the big puts and takes for the quarter.

    是的。先談稅務。我們只是提供了影響稅務的整體重點摘要。我們原先指引是 21%,最後是 19.5%。所以你大致可以說,我們稅率少了 1.5 個百分點,是有幾個因素比我們指引時稍微有利一些。但那兩項只是本季主要的加減項。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • As far as the price elasticity curves by docs going forward or whatever, yes, I don't have any comments on that or, really, any projections of what that's going to be. And then we talked about those things. We talk about segments, would it be lower segments or comprehensive segments, routine segments and those kinds of things, but we don't necessarily have that data by doctor or doctor tiers or where it's going to. And if we did have, I'm not so sure we'd share that anyhow. We just like to keep it high level. But I'd just tell you that we're aware of these price elasticity curves from a specific, not just demographic, but a specific area of the marketplace all over the world. And we'd have to do promotions and things to test those. And then obviously, we'll respond to those either favorably or not, depending on what signals we get. It's an important part of why we do these programs.

    至於未來按醫師來看的價格彈性曲線之類的,是的,我對此沒有任何評論,也沒有任何預測它會變成什麼樣子。我們也談過這些事情。我們會談分群,可能是較低分群或綜合分群、常規分群之類,但我們不一定有按醫師、或醫師層級來看的資料,或它會走向哪裡。即便我們有,我也不太確定我們是否會分享。我們比較希望維持在高層次的說法。但我可以告訴你,我們確實了解這些價格彈性曲線,這是來自市場中特定的面向,不只是人口統計,而是全球各地市場的特定區域。我們必須透過促銷等方式來測試這些。然後顯然,我們會根據收到的訊號,做出正向或不正向的回應。這也是我們之所以做這些方案的重要原因之一。

  • Shirley Stacy - VP of Corporate Communications & IR

    Shirley Stacy - VP of Corporate Communications & IR

  • Thanks, Chris. Well, thank you, everyone. That concludes our conference call today. If you have any further questions, please contact Investor Relations, and we look forward to seeing you at the upcoming conferences and at the Invisalign Ortho Summit next month. Have a great day.

    謝謝你,Chris。好,謝謝各位。今天的電話會議到此結束。如果您還有任何問題,請聯絡投資人關係部門;我們也期待在接下來的各場會議,以及下個月的 Invisalign Ortho Summit 與各位見面。祝各位有美好的一天。

  • Operator

    Operator

  • This concludes today's conference. You may disconnect your lines at this time. Thank you for your participation.

    今天的會議到此結束。您現在可以掛斷電話線。感謝您的參與。